documents incorporated reference incorporated scheringplough corporation proxy statement annual meeting shareholders may part iiitable contents p age part item business item risk factors item b unresolved staff comments item properties item legal proceedings item submission matters vote security holders executive officers registrant part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report internal control financial reporting part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures exev employment agreement exevi employment agreement exeviii employment agreement exeix form change employment agreement exl supplemental executive retirement plan ex computation ratio earnings fixed charges ex subsidiaries ex consent independent registered public accounting firm ex independent auditor 's consent ex power attorney ex certification ex certification ex certification ex certification table contents part item business overview business scheringplough refers scheringplough corporation subsidiaries except otherwise indicated context schering corporation predecessor company incorporated new york new jersey trademarks indicated capital letters k property licensed promoted distributed scheringplough corporation subsidiaries related companies scheringplough global sciencebased health care company leading prescription consumer animal health products internal research collaborations business partners scheringplough discovers develops manufactures markets advanced drug therapies meet important medical needs scheringploughs vision earn trust physicians patients customers serves around world well shareholders scheringplough scheringploughs worldwide headquarters kenilworth new jersey website wwwscheringploughcom april board directors named fred hassan new chairman board chief executive officer scheringplough leadership strategic plan initiated goals stabilizing repairing turning around scheringplough produce longterm value shareholders plan six eightyear action agenda implemented new leadership team recruited mr hassan scheringplough announced entered fourth action agendas five phases slightly ahead schedule segment information new management team reorganized business one managed along geographic lines primary segments us restofworld business organized around products currently scheringplough three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent scheringploughs current management reporting structure prescription pharmaceuticals prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products within prescription pharmaceutical segment three areas focus primary care specialty care cholesterol franchise principal products segment include primary care allergyrespiratory nasonex oncedaily nasalinhaled steroid nasal allergy symptoms including congestion treatment nasal polyps patients years age older clarinex nonsedating antihistamine treatment allergic rhinitis foradil aerolizer longacting betaagonist marketed scheringplough united states maintenance treatment asthma chronic obstructive pulmonary disease acute prevention exerciseinduced bronchospasm asmanex twisthaler oral drypowder corticosteroid inhaler firstline maintenance treatment asthma proventil albuterol inhaler relief bronchospasm patients years older antibiotics avelox broadspectrum fluoroquinolone antibiotic certain respiratory skin infections cipro broadspectrum fluoroquinolone antibiotic certain respiratory skin urinary tract infections dermatologicals elocon mediumpotency topical steroid cream lotion ointment disorders levitra phosphodiesterase type inhibitor pde comarketed scheringplough united states treatment male erectile dysfunction table contents specialty care antiinflammatories remicade antitnf antibody marketed scheringplough outside united states japan certain asian markets treatment rheumatoid arthritis crohns disease ankylosing spondylitis ulcerative colitis psoriatic arthritis psoriasis firstline therapy treatment early rheumatoid arthritis antivirals pegintron powder injection pegylated interferon product chronic hepatitis c approved dosing according patient body weight intron injection chronic hepatitis b c antiviral indications rebetol capsules use pegintron intron chronic hepatitis c oncology temodar capsules certain types brain tumors including newly diagnosed glioblastoma multiforme caelyx longcirculating pegylated liposomal formulation cancer drug doxorubicin marketed scheringplough outside united states treatment certain ovarian cancers kaposis sarcoma metastatic breast cancer intron injection marketed numerous anticancer indications worldwide including adjuvant therapy malignant melanoma antifungals noxafil oral suspension prophylaxis prevention treatment eu invasive fungal infections highrisk patients treatment oropharyngeal candidiasis us eu acute coronary care integrilin injection platelet receptor gp iibiiia inhibitor treatment patients acute coronary syndrome undergoing percutaneous coronary intervention united states well prevention early myocardial infarction patients acute coronary syndrome countries disorders subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone marketed schering plough certain countries outside united states treatment opiate addiction cholesterol franchise zetia novel cholesterolabsorption inhibitor discovered scheringplough scientists use monotherapy combination either statins fenofibrate lower cholesterol vytorin cholesterollowering tablet combining dual action zetia merck co incs statin zocor consumer health care consumer health care segment develops manufactures markets otc foot care sun care products principal products segment include overthecounter otc products claritin nonsedating antihistamines drixoral cold allergy allergy sinus flu nasal decongestant tablets afrin nasal decongestant spray correctol laxative tablets foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils lipprotection products sunless tanning products solarcaine sunburn relief products animal health animal health segment discovers develops manufactures markets animal health products principal products segment include livestock products nuflor bovine swine antibiotic banamine bovine swine antiinflammatory mpac swine pneumonia vaccine table contents poultry products paracox coccivac coccidiosis vaccines poultry companion animal products otomax steroid otitis dogs exspot topical insecticide dogs homeagain pet recovery service zubrin anti inflammatoryanalgesic dogs aquaculture products slice parasiticide sea lice salmon aquaflor antibiotic farmraised fish net sales segment ea r ended decemb er dollars millions prescription pharmaceuticals consumer health care animal health consolidated net sales profit segment e r ended decem r dollars millions prescription pharmaceuticals consumer health care animal health corporate including net interest income million million respectively million net interest expense consolidated profitloss tax cumulative effect change accounting principle scheringploughs net sales include sales vytorin zetia managed partnership merck scheringplough accounts joint venture equity method accounting see note equity income cholesterol joint venture item financial statements supplementary data additional information equity income cholesterol joint venture included prescription pharmaceuticals segment profit corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies item financial statements supplementary data corporate includes special charges million primarily related changes streamlining scheringploughs manufacturing operations us puerto rico announced june related prescription pharmaceuticals segment included cost sales charges approximately million manufacturing streamlining actions primarily related prescription pharmaceuticals segment corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve approximately million representing scheringploughs current estimate resolve massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters item financial statements supplementary data estimated charges relate reportable table contents segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs well million asset impairment charges estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million see note special charges manufacturing streamlining item financial statements supplementary data additional information strategic alliances scheringplough markets products developed internal research products licensed business partners strategic alliances addition merckscheringplough joint ventures strategic alliance centocor described detail scheringplough engaged number alliances including scheringplough exclusive rights us puerto rico strategic agreement bayer market sell distribute bayers avelox moxifloxacin hci cipro ciprofloxacin hci antibiotics undertake bayers us commercialization activities erectile dysfunction medicine levitra vardenafil hci bayers co promotion agreement glaxosmithkline plc licensing agreement millenium pharmaceuticals inc scheringplough markets integrilin eptifibatide injection gp iibiiia inhibitor us certain countries outside us license agreement alza corporation division johnson johnson scheringplough markets caelyx outside united states japan israel treatment certain cancers caelyx marketed doxil us ortho biotech products lp scheringplough exclusive marketing rights suboxone subutex europe canada certain countries suboxone subutex developed reckitt benckiser healthcare ltd treatment opioid dependence within framework medical social psychological treatment products marketed us reckitt benckiser pharmaceuticals inc scheringplough also entered strategic alliances development commercialization new drug therapies including following scheringplough global collaboration novartis ag develop commercialize new combination therapy using new molecular entity nme treat asthma chronic obstructive pulmonary disease copd scheringploughs oncedaily inhaled corticosteroid mometasone active ingredient asmanex mometasone furoate novartis oncedaily betaagonist indacaterol qab combined single inhalation device combination product oncedaily dosing potential offer patient benefits including enhanced disease control convenience scheringplough entered north american development marketing agreement alkabello tabletbased sublingual immunotherapy slit compounds treatment certain allergies one compound grasspollen allergies currently phase iii clinical development us scheringplough entered definitive licensing agreements valeant pharmaceuticals international metabasis therapeutics inc exclusive worldwide development commercial rights pradefovir investigational oral antiviral compound currently phase ii clinical development treatment chronic hepatitis b scheringplough entered exclusive worldwide agreement anacor pharmaceuticals develop market investigational compound topical treatment onychomycosis nail fungus compound currently phase ii clinical development table contents scheringplough announced entered exclusive north american licensing agreement santarus inc development commercialization lowdose form zegerid overthecounter use heartburnrelated indications zegerid immediaterelease proton pump inhibitor currently sold prescription product information merckscheringplough joint ventures may scheringplough merck co inc merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies cholesterol agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either schering plough merck cholesterol agreements provide scheringplough merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched several international markets scheringplough utilizes equity method accounting cholesterol joint venture see note equity income cholesterol joint venture item financial statements supplemental data additional information regarding profits costs sharing accounting provided cholesterol agreements allergyasthma agreements provide joint development marketing partners oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merckscheringplough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis although claritin singulair combination tablet approval country phase iii clinical development ongoing information centocor licenses remicade licensed manufactured centocor inc johnson johnson company scheringplough exclusive marketing rights product outside us japan certain asian markets scheringplough exercised option contract centocor license rights develop commercialize golimumab fully human monoclonal antibody territories remicade golimumab currently phase iii trials scheringplough centocor collaborating resolving difference parties opinions expiration date scheringploughs rights golimumab august scheringplough received determination arbitration rights market golimumab extend years first commercial sales territories centocor appealed ruling global operations nonus operations generate majority scheringploughs profits cash flow nonus activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition scheringplough represented markets licensees distribution table contents arrangements currently scheringplough business operations countries approximately employees outside us nonus operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing reimbursement restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact scheringploughs consolidated financial results additional information global operations see item managements discussion analysis segment information described net sales geographic area dollars millions united states europe canada pacific area asia latin america total international consolidated net sales scheringplough subsidiaries countries outside us net sales presented geographic area scheringploughs customers located following countries accounted percent consolidated net sales past three years consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions total international net sales france japan canada italy net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated net consolidated net consolidated net sales net sales sales net sales sales net sales dollars millions mckesson corporation cardinal health table contents supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows mount p ercentage dollars millions us nasonex international remicade pegintron longlived assets geographic location dollars millions united states singapore ireland puerto rico total longlived assets shown geographic location primarily property scheringplough disaggregate assets segment basis internal management reporting therefore information presented research development scheringploughs research activities primarily aimed discovering developing new prescription products enhancements existing prescription products medical commercial significance companysponsored research development expenditures billion billion billion respectively percentage consolidated net sales research development expenditures represented approximately percent percent percent respectively scheringploughs research activities concentrated therapeutic areas respiratory diseases inflammatory diseases infectious diseases oncology cardiovascular metabolic diseases central nervous system disorders scheringplough also substantial efforts directed toward biotechnology immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale schering ploughs product pipeline lists significant products development available scheringploughs website wwwscheringploughcom due nature development approval process well fact human health involved science human health constantly evolving status compounds development subject change schering plough assume duty update information four scheringploughs phase ii projects granted fasttrack designation fda novel thrombin receptor antagonist acute coronary syndrome secondary prevention subsequent cardiovascular events vicriviroc hiv protease inhibitor compound hepatitis c new potential treatment patients parkinsons disease products advance phase iii clinical trials significant expenditures would required due large number patients necessary phase iii trials table contents patents trademarks intellectual property rights overview intellectual property protection critical scheringploughs ability successfully commercialize product innovations scheringplough owns applied licensed rights large number patents us countries relating molecules products product uses formulations manufacturing processes assurance patents scheringplough seeking granted patents scheringplough granted would found valid challenged moreover patents relating particular molecules products uses formulations processes preclude manufacturers employing alternative processes marketing alternative products formulations might successfully compete scheringploughs patented products outside us standard intellectual property protection pharmaceuticals varies widely many countries reasonably strong patent laws countries currently provide little effective protection inventions intellectual property rights traderelated aspects intellectual property agreement trips administered world trade organization wto countries agreed provide nondiscriminatory protection pharmaceutical inventions assure adequate effective rights available patent owners possible changes agreement made future diminish delay implementation developing countries soon assess much scheringplough impacted commercially changes product patent expires patent holder often loses effective market exclusivity product result rapid sharp material decline sales formerly patented product particularly us however cases innovator company obtain additional commercial benefits manufacturing trade secrets laterexpiring patents processes uses formulations trademark use exclusivity may available pharmaceutical regulatory laws scheringploughs intellectual property portfolio patent protection certain scheringplough molecules products processes uses important scheringploughs business financial results many scheringploughs products addition patents compound scheringplough holds patents manufacturing processes formulations uses may extend exclusivity beyond expiration compound patent scheringploughs subsidiaries licensed rights number patents patent applications us abroad patents patent applications relating scheringploughs significant products including without limitation vytorin zetia remicade nasonex intron pegintron temodar clarinex material importance scheringplough worldwide scheringplough sells major products trademarks also material aggregate business financial results trademark protection varies throughout world protection continuing countries long mark used countries long registered registrations normally fixed renewable terms patent challenges hatchwaxman act drug price competition patent term restoration act commonly known hatchwaxman made complex set changes patent new drug approval laws us hatchwaxman drug could approved without providing us food drug administration fda complete safety efficacy studies known complete new drug application nda hatchwaxman authorizes fda approve generic versions innovative medicines without information upon filing abbreviated new drug application anda anda generic manufacturer must demonstrate bioequivalence generic version ndaapproved drug safety efficacy hatchwaxman provides limited patent term restoration partially make patent term lost time ndaapproved drug regulatory review ndaapproved drugs also receive limited period data exclusivity prevents approval anda applications specific time periods approval ndaapproved drug table contents absent successful patent challenge fda approve anda innovators patents expire however generic manufacturer may file anda seeking approval expiration applicable data exclusivity alleging one patents listed innovators nda invalid infringed allegation commonly known paragraph iv certification innovator must file suit generic manufacturer protect patents one ndalisted patents successfully challenged first filer paragraph iv certification may entitled day period market exclusivity generic manufacturers recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue number generic companies filed andas clarinex tablets reditabs response scheringplough brought patent infringement actions adverse outcome action may result introduction generic desloratadine prior expiration patents subject litigations addition february schering plough received notice generic company indicating filed anda zetia challenging us patents listed zetia merck scheringplough considering appropriate response marketing activities competition scheringplough trained professional sales representatives introduces makes known prescription drugs physicians pharmacists hospitals managed care organizations buying groups scheringplough sells prescription drugs hospitals certain managed care organizations wholesale distributors retail pharmacists scheringplough also introduces makes known prescription products journal advertising direct mail advertising distribution samples physicians television radio internet print advertising media scheringplough trained professional sales representatives promotes animal health products veterinarians distributors animal producers scheringplough sells overthecounter foot care sun care products wholesale retail drug food chain mass merchandiser outlets scheringplough promotes directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies significantly larger scheringplough substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used scheringplough products include research development new improved products varied dosage forms strengths switching prescription products nonprescription status us many scheringploughs products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products competing products therapeutic category longer protected patents exclusivity available pharmaceutical regulatory laws scheringplough operates primarily prescription pharmaceutical marketplace however appropriate scheringplough seeks regulatory approval switch prescription products overthecounter status means extending products life cycle way otc marketplace another means maximizing return investments discovery development government regulation scheringploughs major business segments subject significant regulation multiple jurisdictions section describes general regulatory framework additional information cost regulatory compliance specific impacts scheringploughs business financial condition described heading regulatory competitive environment scheringplough operates item managements discussion analysis additional information regulatory matters found table contents item legal matters note consent decree note legal environmental regulatory matters item financial statements supplementary data prescription drug segment regulations apply phases business including regulatory requirements conduct standards clinical trials example requiring use good clinical practices gcps apply research development stage regulatory requirements conduct standards postapproval clinical trials required regulatory approval begin marketing new drug market existing drug product new indications regulations prescribing manner drugs manufactured packaged labeled advertised marketed distributed regulations impacting pricing drugs regulatory requirements assess report adverse impacts side effects drugs used clinical trials well marketed drugs called pharmacovigilance ability regulatory authorities remove product market recall certain batches products us national regulation phases prescription drug business except pricing centralized food drug administration fda fda responsible protecting us public health assuring safety efficacy security human veterinary drugs biological products medical devices generally free market pricing us although centers medicare medicaid services cms medicare part b include provisions pricing drugs elderly disabled indigent receive federal prescription benefits scheringplough also committed complying voluntary best practices pharmaceutical research manufacturers america phrma trade industry group member regarding marketing advertising practices european union eu including scheringploughs key markets united kingdom france germany italy regulation local country level additional regulation eu level european medicines agency emea pharmaceutical products regulated levels various national mutual recognition centralized regulatory procedures emea coordinates evaluation supervision medicinal products throughout eu paneu market pricing system however individual member states various systemsagencies regulate price local level japan regulation pharmaceuticals medical device agency pmda pmda regulates pharmaceuticals medical devices development post marketing use japanese government regulates pricingreimbursement pharmaceutical products japan complicated pricing process includes benchmarks prices western countries us canada select eu countries major countries influence pricing even cms united states increasing pressure pharmaceutical industry bring products market provide differentiation versus existing products lead expensive scientifically challenging clinical trials order generate type data new products versus marketed comparators raw materials raw materials essential scheringploughs operations available adequate quantities number potential suppliers energy expected available scheringplough sufficient quantities meet operating requirements seasonality certain scheringploughs products particularly respiratory sun care categories seasonal nature seasonal patterns pronounced effect consolidated operations scheringplough table contents environment date compliance federal state local laws regarding discharge materials environment protection environment material effect schering ploughs capital expenditures earnings competitive position employees december scheringplough employed approximately people worldwide available information scheringploughs ks qs ks amendments reports filed furnished sec available free charge scheringploughs website soon reasonably practicable materials electronically filed sec scheringploughs address world wide web wwwscheringploughcom since scheringplough began practice third quarter report available scheringploughs website within hours filing reports filed scheringplough sec may read copied secs public reference room f street ne washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec item risk factors scheringploughs future operating results cash flows may differ materially results described k due risks uncertainties related scheringploughs business including discussed addition factors represent risks uncertainties could cause actual results differ materially implied forwardlooking statements contained report key scheringplough products generate significant amount scheringploughs profits cash flows events adversely affect market leading products could material negative impact results operations cash flows scheringploughs ability generate profits operating cash flow largely dependent upon continued profitability scheringploughs cholesterol franchise consisting vytorin zetia addition products pegintron rebetol remicade temodar otc claritin nasonex accounted material portion revenues result scheringploughs dependence key products events adversely affect markets products could significant impact results operations events include loss patent protection increased costs associated manufacturing otc availability scheringploughs product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason example profitability scheringploughs cholesterol franchise may adversely affected introduction multiple generic forms december two competing cholesterol products lost patent protection earlier year recent years market pegintron rebetol adversely affected result introduction competitors product pegylated interferon introduction generic ribavirin value pegintron pegylated interferon rebetol ribavirin combination therapy hepatitis severely diminished earnings cash flow materially negatively impacted high risk funds invested research generate financial returns development novel drugs requires significant expenditures low probability success high rate failure inherent research develop new drugs treat diseases result high risk funds invested research programs generate financial returns risk profile table contents compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested scheringploughs success dependent development marketing new products uncertainties regulatory approval process may result failure products reach market products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others intellectual property protection innovation important contributor scheringploughs profitability generic forms scheringploughs products may introduced market result expiration patents covering scheringploughs products successful challenge scheringploughs patent atrisk launch generic version scheringplough product may material negative effect results operations intellectual property protection critical scheringploughs ability successfully commercialize products upon expiration successful challenge scheringploughs patents covering product competitors may introduce lowerpriced generic versions products may include scheringploughs wellestablished products recent years generic manufacturers launched generic versions products ultimate resolution patent litigation commonly known atrisk product launches generic competition could result loss significant portion sales downward pressures prices scheringplough offers formerly patented products particularly us patents patent applications relating scheringploughs significant products material importance scheringplough additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect scheringploughs results operations patent disputes costly prosecute defend adverse judgments could result damage awards increased royalties similar payments decreased sales patent positions highly uncertain patent disputes pharmaceutical industry unusual adverse result patent dispute involving scheringploughs patents patents collaborators may lead loss market exclusivity render patents invalid adverse result patent dispute involving patents held third party may preclude commercialization scheringploughs products force scheringplough obtain licenses order continue manufacturing marketing affected products licenses may available commercially reasonable terms negatively affect sales existing products result injunctive relief payment financial remedies example scheringploughs product dr scholls freeze away wart removal product currently subject patent infringement action brought third party company adverse outcome action may result scheringploughs inability continue manufacturing product even scheringplough ultimately successful particular dispute scheringplough may incur substantial costs defending patents intellectual property rights example generic manufacturer may file abbreviated new drug application seeking approval expiration applicable data exclusivity alleging one patents listed innovators new drug table contents application invalid infringed allegation commonly known paragraph iv certification innovator ability file suit generic manufacturer enforce patents recent years generic manufacturers used paragraph iv certifications extensively challenge patents wide array innovative pharmaceuticals anticipated trend continue potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights see patent challenges hatchwaxman act item business discussion current paragraph iv certifications scheringplough products us foreign regulations including establishing scheringploughs ability price products may negatively affect scheringploughs sales profit margins scheringplough faces increased pricing pressure us abroad managed care organizations institutions government agencies programs could negatively affect scheringploughs sales profit margins example medicare prescription drug improvement modernization act contains prescription drug benefit individuals eligible medicare prescription drug benefit became effective january resulting increased use generics increased purchasing power negotiating behalf medicare recipients addition legislation concerning price controls trends could affect scheringploughs business include legislative regulatory action relating pharmaceutical pricing reimbursement health care reform initiatives drug importation legislation involuntary approval medicines otc use consolidation among customers trends toward managed care health care costs containment result us governments efforts reduce medicaid expenses managed care organizations continue grow influence scheringplough faces increased pricing pressure managed care organizations continue seek price discounts respect scheringploughs products outside us many governmental agencies strictly control directly indirectly prices pharmaceutical products sold international markets cost control methods including restrictions physician prescription levels patient reimbursements emphasis greater use generic drugs acrosstheboard price cuts may decrease revenues internationally material pending government investigations scheringplough could lead commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs could give rise investigations litigation government entities private parties scheringplough predict certainty outcome pending investigations subject may lead judgment settlement involving significant monetary award restrictions operations pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs addition adverse outcome government investigation could prompt government entities commence investigations scheringplough cause entities private parties bring civil claims scheringplough also predict whether table contents investigations affect marketing practices sales result could material adverse impact scheringploughs results operations cash flows financial condition business regardless merits outcomes investigations government investigations costly divert managements attention scheringploughs business may result substantial damage scheringploughs reputation please refer item legal proceedings descriptions pending investigations legal matters adverse outcomes could negatively affect scheringploughs business unfavorable outcomes pending litigation matters future litigation including litigation concerning product pricing securities law violations product liability claims erisa matters patent intellectual property disputes antitrust matters could preclude commercialization products negatively affect profitability existing products could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs result could materially adversely affect scheringploughs results operations cash flows financial condition business please refer item legal proceedings descriptions significant pending litigation scheringplough subject governmental regulations failure comply well costs compliance regulations may adversely affect scheringploughs financial position results operations scheringploughs manufacturing facilities clinicalresearch practices must meet stringent regulatory standards subject regular inspections cost regulatory compliance including associated compliance failures materially affect scheringploughs financial position results operations failure comply regulations include pharmacovigilance reporting requirements standards relating clinical laboratory manufacturing practices result delays approval drugs seizure recalls drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions example may scheringplough agreed fda entry consent decree resolve issues related compliance current good manufacturing practices certain scheringploughs facilities new jersey puerto rico consent decree work placed significant additional controls production release products sites increased costs slowed production led reduction number products produced sites scheringploughs research development operations negatively impacted consent decree operations share common facilities manufacturing operations scheringplough also subject regulations including environmental health safety labor regulations developments following regulatory approval may decrease demand scheringploughs products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials may decrease demand scheringploughs products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed uncertainties concerning safety labeling changes greater scrutiny advertising promotion table contents past several years clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products situations also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition following wake recent product withdrawals companies significant safety issues health authorities fda european medicines agency pharmaceuticals medicines device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially us advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase prevalence negative publicity regarding known side effects scheringploughs products could significantly reduce demand product may require scheringplough remove product market current environment pharmaceutical companies operate scheringplough risk product liability claims products new products technological advances developed scheringploughs competitors may negatively affect sales scheringplough operates highly competitive industry scheringplough competes large number multinational pharmaceutical companies biotechnology companies generic pharmaceutical companies many scheringploughs competitors conducting research development areas served scheringploughs current products products scheringplough process developing competitive developments may impact scheringplough include technological advances patents granted new products developed competitors new existing generic prescription andor otc products compete products scheringplough merckscheringplough cholesterol partnership addition possible doctors patients providers may favor products offered competitors due safety efficacy pricing reimbursement characteristics result scheringplough unable maintain sales products competition third parties may make difficult scheringplough acquire license new products product candidates regardless stage development enter transactions terms permit scheringplough generate positive financial impact scheringplough depends acquisition inlicensing arrangements source new products opportunities obtaining licensing new products limited however securing rights typically requires substantial amounts funding substantial resource commitments scheringplough competes opportunities many companies third parties greater financial resources greater ability make resource commitments scheringplough may able acquire license new products could adversely impact scheringplough prospects scheringplough may also difficulty acquiring licensing new products acceptable terms secure rights new products schering plough may make substantial financial resource commitments could limit ability produce positive financial impact transactions scheringplough relies thirdparty relationships key products conduct changing circumstances third parties may adversely impact business scheringplough several relationships third parties scheringplough depends many key products often third parties compete scheringplough interests aligned interests scheringplough notwithstanding contracts scheringplough third parties table contents scheringplough may able control influence conduct parties circumstances affect either could adversely impact scheringplough scheringplough operates global business exposes scheringplough additional risks adverse events could material negative impact results operations scheringplough operates countries nonus operations generate majority scheringploughs profit cash flow nonus operations subject certain risks inherent conducting business overseas risks include changes foreign medical reimbursement policies programs pricing restrictions multiple foreign regulatory requirements could restrict scheringploughs ability manufacture sell products fluctuations inflation interest rate foreign currency exchange rates trade protection measures import export licensing requirements diminished protection intellectual property countries possible nationalization expropriation addition may changes scheringploughs business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease insurance coverage product liability may become unavailable cost prohibitive scheringplough maintains insurance coverage deductibles selfinsurance reflect market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly however result increased product liability claims pharmaceutical industry availability third party insurance may become unavailable cost prohibitive scheringplough subject evolving complex tax laws may result additional liabilities may affect results operations scheringplough subject evolving complex tax laws us foreign jurisdictions significant judgment required determining scheringploughs tax liabilities scheringploughs tax returns periodically examined various tax authorities scheringploughs us federal income tax returns period currently audit internal revenue service scheringplough may challenged irs tax authorities positions taken income tax returns although scheringplough believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition scheringplough may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions item b unresolved staff comments none table contents item properties scheringploughs corporate headquarters located kenilworth new jersey principal research facilities located kenilworth union summit new jersey palo alto california cambridge massachusetts elkhorn nebraska principal manufacturing facilities follows location product type belgium pharmaceuticals cleveland tennessee usa consumer products ireland pharmaceuticals consumer products animal health kenilworth new jersey usa pharmaceuticals consumer products mexico pharmaceuticals omaha nebraska usa animal health puerto rico pharmaceuticals singapore pharmaceuticals scheringplough owns properties exception massachusetts research facility general properties adequately maintained suitable purposes discussed detail part ii k certain scheringploughs manufacturing sites operate capacity scheringplough took actions streamline manufacturing operations continues work enhancing longterm competitiveness see item management discussion analysis note special charges manufacturing streamlining note consent decree item financial statements supplementary data additional information scheringplough currently process building us pharmaceutical sciences center new jersey capital expenditures approximately million made related center additional capital expenditures approximately million expected next three years scheringplough also upgrading processes systems strengthening talent rd area item legal proceedings material pending legal proceedings ordinary routine litigation incidental business scheringplough corporation subsidiaries property subject disclosed additional information legal proceedings including important financial information found litigation charges discussion note special charges manufacturing streamlining item managements discussion analysis note legal environmental regulatory matters contained item financial statements supplementary data patent matters described patents trademarks intellectual property rights item business intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect scheringplough dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages table contents massachusetts investigation august scheringplough announced reached agreement us attorneys office district massachusetts settle investigation involving schering ploughs sales marketing clinical trial practices programs along warrick pharmaceuticals warrick scheringploughs generic subsidiary massachusetts investigation investigation focused following alleged practices providing remuneration managed care organizations physicians others induce purchase schering pharmaceutical products offlabel marketing drugs submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program agreement provided aggregate settlement amount million criminal fine million million resolve civil aspects investigation january schering sales corporation subsidiary scheringplough pled guilty one count conspiracy make false statements government connection settlement scheringplough signed addendum existing corporate integrity agreement office inspector general us department health human services addendum affect schering ploughs ongoing business customers including federal government scheringplough recorded liability million related massachusetts investigation well investigations state litigation described awp litigation investigations settlement amount million relates massachusetts investigation awp litigation investigations ongoing awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities laws allegedly failing disclose material information making material misstatements specifically allege scheringplough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks compensatory damages behalf class court certified shareholder class october discovery ongoing table contents shareholder derivative actions two lawsuits filed us district court district new jersey scheringplough certain officers directors former director seeking damages behalf scheringplough including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints allege failure disclose material information breach fiduciary duty directors relating fda inspections investigations scheringploughs pricing practices sales marketing clinical trials practices lawsuits shareholder derivative actions purport assert claims behalf scheringplough two shareholder derivative actions pending us district court district new jersey consolidated one action august erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anticompetitive effects settlements alleged class action suits filed federal state courts behalf direct indirect purchasers k dur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages discovery ongoing thirdparty payor actions several purported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase scheringploughs tax reserves adequate cover abovementioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection table contents settlement massachusetts investigation commencing new fiveyear term disclosed note consent decree scheringplough subject obligations consent decree fda failure comply obligations cia consent decree result financial penalties discussion pending pharmacovigilance matters resulting pharmacovigilance inspections officials british french medicines agencies conducted request european medicines agency emea refer regulatory competitive environment scheringplough operates item managements discussion analysis matters nitrodur investigation august scheringplough received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning scheringploughs classification nitrodur medicaid rebate purposes scheringploughs use nominal pricing bundling product sales scheringplough cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates senate finance committee inquiry january united states senate committee finance followed previous requests scheringplough request information scheringploughs practices relating educational grants scheringplough understands committee directed similar followup requests pharmaceutical companies scheringplough cooperating committee responded requests french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies item submission matters vote security holders applicable table contents executive officers registrant listed executive officers corporate officers scheringplough february unless otherwise indicated held position indicated past five years officers serve one year successors duly appointed name title ag e robert j bertolini executive vice president chief financial officer john carroll vice president global internal audits c ron cheeley senior vice president global human resources carrie cox executive vice president president global pharmaceuticals william j creelman vice president tax fred hassan chairman chief executive officer steven h koehler vice president controller thomas p koestler phd executive vice president president scheringplough research institute raul e kohan senior vice president president animal health joseph j larosa vice president legal affairs ian mcinnes senior vice president global supply chain e kevin moore vice president treasurer lori queisser senior vice president global compliance business practices thomas j sabatino jr executive vice president general counsel karl salnoske vice president chief information officer brent saunders senior vice president president consumer health care susan ellen wolf corporate secretary associate general counsel vice president corporate governance officers defined rule af securities exchange act mr bertolini joined scheringplough executive vice president chief financial officer mr bertolini partner pricewaterhousecoopers mr carroll joined scheringplough vice president global internal audits mr carroll vice president general auditor american standard companies general auditor american standard companies assistant treasurer bristolmyers squibb mr cheeley joined scheringplough senior vice president global human resources mr cheeley group vice president global compensation benefits pharmacia corporation ms cox joined scheringplough executive vice president president global pharmaceuticals ms cox executive vice president president global prescription business pharmacia corporation mr creelman joined scheringplough vice president tax mr creelman senior tax counsel pfizer mr creelman assistant vice president international tax cigna corporation mr hassan joined scheringplough chairman board chief executive officer mr hassan chairman board chief executive officer pharmacia corporation table contents mr koehler joined scheringplough vice president controller mr koehler senior vice president chief financial officer treasurer vice president chief financial officer treasurer corporate secretary medicines company dr koestler named executive president president scheringplough research institute september dr koestler executive vice president global development scheringplough research institute september executive vice president scheringplough research institute senior vice president global regulatory affairs pharmacia corporation mr kohan named senior vice president president animal health february mr kohan appointed president scheringplough animal health became group head specialty operations mr larosa became vice president legal affairs mr larosa staff vice president secretary associate general counsel dr mcinnes joined scheringplough senior vice president global supply chain dr mcinnes executive vice president supply chain watson pharmaceuticals inc senior vice president global supply chain pharmacia corporation ms queisser joined scheringplough february senior vice president global compliance business practices ms queisser vice president chief compliance officer october february executive director general auditor march october eli lilly company mr sabatino joined scheringplough executive vice president general counsel mr sabatino senior vice president general counsel baxter international inc mr salnoske joined scheringplough vice president chief information officer mr salnoske ceo adaptive trade mr saunders appointed senior vice president president consumer health care february mr saunders joined scheringplough senior vice president global compliance business practices mr saunders partner pricewaterhousecoopers ms wolf named vice president corporate secretary associate general counsel held various positions scheringploughs law department table contents part ii item market registrants common equity related stockholder matters principal market scheringploughs common stock new york stock exchange additional information required item incorporated reference table captioned quarterly data unaudited item financial statements supplementary data following table provides information respect purchases scheringplough common shares fourth quarter issuer purchases equity securities total number maximum number shares purchased shares may average part publicly yet purchased total number price paid announced plans plans period shares purchased per share programs programs october october na na november november na na december december na na total october december na na shares included table repurchased pursuant scheringploughs stock incentive program represent shares delivered scheringplough option holders payment exercise price tax withholding obligations connection stock options stock awards table contents performance graph comparison cumulative total return five years ended december scheringplough corporation composite peer group sp index graph assumes investment december reinvestment dividends scheringploughs common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company merck co inc pfizer inc wyeth warner lambert company pharmacia corporation longer publicly traded acquired pfizer inc longer included peer index table contents item selected financial data millions except per share figures percentages operating results net sales equity income cholesterol joint venture incomeloss income taxes net incomeloss net incomeloss available common shareholders diluted earningsloss per common share basic earningsloss per common share research development expenses depreciation amortization expenses financial position cash flows property net total assets longterm debt shareholders equity capital expenditures financial statistics net incomeloss percent net sales return average shareholders equity net book value per common share data cash dividends per common share cash dividends paid common shares cash dividends preferred shares average shares outstanding used calculating diluted earningsloss per common share average shares outstanding used calculating basic earningsloss per common share common shares outstanding yearend include special charges manufacturing streamlining costs respectively see note special charges manufacturing streamlining additional information charges incurred special charges incurred included increases litigation reserves million million respectively resulted investigations scheringploughs sales marketing practices special charges also included approximately million employee termination costs related voluntary early retirement program announced august million asset impairment charges related closure manufacturing facility united kingdom writedown production equipment related products longer going produced manufacturing site operating fda consent decree writedown drug license sun care trade name expected cash flows support carrying value assumes conversion preferred shares approximately million common shares million common shares million common shares table contents item managements discussion analysis financial condition results operations executive summary overview scheringplough scheringplough discovers develops manufactures markets medical therapies treatments enhance human health scheringplough also markets leading consumer brands overthecounter otc foot care sun care markets operates global animal health business two sources new products products acquired acquisition licensing arrangements products scheringploughs latestage research pipeline respect acquisitions licensing scheringplough recently acquired new product licenses however limited opportunities obtaining licensing critical latestage products positive material financial impact limited opportunities typically require substantial amounts funding scheringplough often competes opportunities companies greater financial resources strategy focused science earlier decade scheringplough experienced number business regulatory legal challenges april board directors named fred hassan new chairman board chief executive officer scheringplough corporation support board recruited new senior executive team initiated strategic plan goal stabilizing repairing turning around scheringplough order build longterm shareholder value strategic plan action agenda six eightyear fivephase plan october scheringplough announced entered fourth phase action agenda build base build base phase scheringplough continues focus strategy value creation across broad front including growing business penetrating new markets expanding existing products discovering developing acquiring new products part effort scheringplough enhancing infrastructure upgrading processes systems strengthening talentboth recruitment talented individuals development key employees efforts companywide scheringplough focusing especially research development key component action agenda applying science meet unmet medical needs research development activities focus mechanisms treat serious diseases result core strategy scheringplough invest substantial funds scientific research goal creating therapies treatments important medical commercial value consistent core strategy scheringplough increasing investment research development scheringploughs progressing pipeline includes drug candidates across wide range therapeutic areas compounds approaching phase development scheringplough continues develop later phase growthdrivers pipeline eg thrombin receptor antagonist golimumab vicriviroc hcv protease inhibitor anticipates higher spending clinical trial activities results highlights scheringploughs performance follows scheringploughs net sales billion increase billion percent compared period net income available common shareholders billion compared million cash flow operating activities billion global sales scheringploughs cholesterol franchise products vytorin zetia made cholesterol joint venture merck company inc merck continued grow significantly contributed scheringploughs improved operating results cash flow addition increased sales table contents pharmaceutical products remicade nasonex temodar clarinex also contributed favorably scheringploughs overall operating results cash flow scheringplough gained approvals new products indications including lifesaving antifungal medicine noxafil oral suspension united states eu prevention invasive fungal infections noxafil discovered scheringploughs research laboratories temodal japan treatment form brain cancer malignant glioma remicade eu ulcerative colitis suboxone sublingual tablets eu opioid dependence scheringplough streamlined global supply chain yield expected annualized cost savings million scheringplough reached agreement us attorneys office district massachusetts us department justice settle previously disclosed investigation related actions took place prior agreement provided aggregate settlement amount million settlement material adverse effect scheringploughs results operations financial condition business strategic alliances typical pharmaceutical industry scheringplough licenses manufacturing marketing andor distribution rights certain products others also manufactures markets andor distributes products owned others pursuant licensing joint venture arrangements time third parties involved additional factors relating third party outside control scheringplough may create positive negative impacts scheringplough vytorin zetia remicade subject arrangements key scheringploughs current business financial performance addition potential strategic alternatives may impacted change control provisions arrangements could result vytorin zetia acquired merck remicade reverting back centocor change control provision relating vytorin zetia included contract merck filed exhibit r scheringploughs k change control provision relating remicade contained contract centocor filed exhibit v scheringploughs k cholesterol franchise scheringploughs cholesterol franchise products vytorin zetia managed joint venture scheringplough merck treatment elevated cholesterol levels zetia scheringploughs novel cholesterol absorption inhibitor vytorin combination zetia zocor mercks statin medication financial commitment compete cholesterol reduction market shared merck profits sales vytorin zetia also shared merck operating results joint venture merck recorded using equity method accounting material change sales market share scheringploughs cholesterol franchise would significant impact scheringploughs results operations cash flows order maintain enhance infrastructure business scheringplough must continue increase profits increased profitability largely dependent upon performance schering ploughs cholesterol franchise cholesterolreduction market single largest pharmaceutical category world vytorin zetia competing market combined basis products continued grow terms market share franchise two products together captured percent total prescriptions us cholesterol management market based january ims data japan included joint venture merck japanese market bayer healthcare comarket scheringploughs cholesterolabsorption inhibitor zetia upon approval scheringplough anticipates receiving approval japan due backlog new drug applications japan scheringplough precisely predict timing approval table contents license arrangements centocor remicade prescribed treatment immunemediated inflammatory disorders rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis remicade scheringploughs second largest marketed pharmaceutical product line cholesterol franchise remicade licensed manufactured centocor inc johnson johnson company scheringplough exclusive marketing rights product outside us japan certain asian markets scheringplough exercised option contract centocor license rights develop commercialize golimumab new tnfalpha monoclonal antibody territories remicade golimumab currently phase iii trials scheringplough centocor collaborating resolving difference parties opinions expiration date scheringploughs rights golimumab august scheringplough received determination arbitration rights market golimumab extend years first commercial sales territories centocor appealed ruling manufacturing sales marketing scheringplough supports commercialized products manufacturing sales marketing efforts scheringplough also moving forward additional investments enhance infrastructure business including capital expenditures drug development process products moved drug discovery pipeline markets information technology systems postmarketing studies monitoring scheringplough continually reviews business including manufacturing operations identify actions enhance longterm competitiveness however scheringploughs manufacturing cost base relatively fixed actions significantly reduce scheringploughs manufacturing infrastructure involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements scheringplough closed one manufacturing plant took streamlining actions scheringplough continues review carrying value manufacturing assets indications impairment future events decisions may lead additional asset impairments related costs regulatory competitive environment scheringplough subject jurisdiction various national state local regulatory agencies regulatory compliance complex costly impacting timing needed bring new drugs market market drugs new indications since scheringplough working us fda consent decree resolve issues involving scheringploughs compliance current good manufacturing practices certain manufacturing sites new jersey puerto rico terms decree provided fda notified scheringplough significant violation fda law regulations decree fiveyear period since decrees entry may scheringplough may petition court decree dissolved fda oppose scheringploughs petition assurance particular date consent decree lifted scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eumember states scheringplough engages clinical trial research many countries around world research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities table contents us many scheringploughs pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts international markets scheringplough operates environment government mandated costcontainment programs market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors loss patent protection due challenges competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature discussion operating results net sales significant portion net sales made major pharmaceutical health care product distributors major retail chains us consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors addition fluctuations sales many pharmaceutical products us subject increased pricing pressure managed care groups institutions government agencies groups seeking discounts scheringplough pharmaceutical manufacturers us market also required provide statutorily defined rebates various government agencies order participate medicaid program veterans health care program governmentfunded programs international markets scheringplough operates environment governments may mandated costcontainment programs placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs consolidated net sales billion increase billion percent compared increase primarily reflected growth sale volumes remicade nasonex pegintron temodar increase also reflected unfavorable impact percent foreign exchange consolidated net sales totaled billion increase billion percent compared reflecting higher volumes remicade nasonex pegintron temodar inclusion full year sales avelox cipro addition foreign exchange favorable impact percent table contents net sales years ended december follows incr e e decre ase dollars millions prescription pharmaceuticals remicade nasonex pegintron clarinexaerius temodar claritin rx integrilin rebetol avelox nm intron caelyx subutex elocon cipro nm pharmaceutical consumer health care otc nm foot care sun care animal health consolidated net sales nm meaningful percentage international net sales remicade drug treatment immunemediated inflammatory disorders rheumatoid arthritis early rheumatoid arthritis psoriatic arthritis crohns disease ankylosing spondylitis plaque psoriasis ulcerative colitis percent billion compared percent million compared due greater demand expanded indications continued market growth competitive products indications referred introduced additional competitive products expected introduced global net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies rose percent million compared percent million compared product captured greater us international market share us sales benefited increased promotional effort introduction new scentfree alcoholfree formulation nasonex nasal spray generic form flonase fluticasone propionate approved early may unfavorably impact corticosteroid nasal spray market going forward global net sales pegintron powder injection pegylated interferon product treating hepatitis c increased percent million compared percent million compared sales increase reflected higher sales volume japan us sales growth due december launch peg intron rebetol combination therapy japan japan sales benefited significant number patients waiting approval pegintron beginning treatment pegintron sales japan begun decline toward end table contents trend expected continue new patient enrollment hepatitis c treatment moderates new competition enters japanese market global net sales clarinex marketed aerius many countries outside us treatment seasonal outdoor allergies yearround indoor allergies increased percent million compared due increased demand europe latin america well increased sales us despite slightly declining market share global net sales clarinex decreased percent million compared primarily due reduced market share declining market us global net sales temodar capsules treatment certain types brain tumors increased percent million compared increased percent million compared increases sales due increased utilization new indications temodar approved us fda treating newly diagnosed glioblastoma multiforme gbm prevalent form brain cancer european commission use combination radiotherapy gbm patients eumember states well iceland norway temodar approved japan treatment malignant glioma growth rates temodar expected moderate significant market penetration already achieved treatment gbm international net sales prescription claritin decreased percent million compared sales increased percent million compared due launch claritin reditabs japan coupled unusually severe japanese allergy season global net sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndrome sold primarily us scheringplough increased percent million compared sales decreased percent million compared effective september scheringplough restructured integrilin copromotion agreement millennium terms restructured agreement scheringplough acquired exclusive us development commercialization rights integrilin exchange upfront payment million royalties integrilin sales restructured agreement calls minimum royalty payments million per year millennium global net sales rebetol capsules use combination pegintron intron treating hepatitis c decreased percent million compared due lower sales europe increased competition global net sales increased percent million compared due primarily launch pegintron rebetol combination therapy japan december japan sales benefited significant number patients waiting approval pegintron beginning hepatitis c treatment sales expected continue decline result moderation hepatitis c patient enrollments japan new competition enters japanese market net sales avelox fluoroquinolone antibiotic treatment certain respiratory skin infections sold primarily us scheringplough result license agreement bayer increased percent million compared million due share growth new indications sales avelox represented initial three months sales agreement bayer effective october global net sales intron injection chronic hepatitis b c antiviral anticancer indications decreased percent million compared percent million compared due conversion pegintron treating hepatitis c japan international net sales caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma increased percent million compared primarily due expanding market product sales increased percent million compared reflecting adoption ovarian cancer metastatic breast cancer indications international net sales subutex tablets treatment opiate addiction increased percent million compared due increased market share sales increased percent million table contents compared due increased market penetration october suboxone approved eu including member states well iceland norway treatment opioid dependence global net sales elocon cream mediumpotency topical steroid decreased percent million compared decreased percent million compared reflecting generic competition introduced us first quarter generic competition expected continue adversely affect sales product net sales cipro fluoroquinolone antibiotic treatment certain respiratory skin urinary tract infections sold primarily us scheringplough result license agreement bayer decreased percent million compared million due market share erosion generic competition sales cipro represented initial three months sales agreement bayer pharmaceutical net sales include large number lower sales volume prescription pharmaceutical products several products sold limited markets outside us many multiple source products longer protected patents products include treatments respiratory cardiovascular dermatological infectious oncological diseases included pharmaceutical sales sales scheringploughs albuterol products fda issued final rule requires cfc albuterol products including scheringploughs proventil cfc removed market later december scheringplough manufacturers albuterol cfc transition albuterol hfa proventil hfa prior yearend deadline scheringplough begun transition hfa product scheringplough uncertain ultimate impact scheringploughs overall future sales proventil products due complexities multiple external factors influencing transition including competing albuterol hfa products global net sales consumer health care products include otc foot care sun care products increased percent million compared reflecting increase sales sun care products dr scholls foot care products sales billion sales otc claritin decreased percent million compared percent million compared result restrictions retail sale otc products containing pseudoephedrine pse addition otc claritin continues face competition private labels branded loratadine net sales sun care products increased million percent compared million percent compared primarily due success new coppertone continuous spray products launched sales sun care products also reflected stronger overall suncare season us future sales difficult predict consumer health care market highly competitive heavy advertising consumers frequent competitive product introductions global net sales animal health products increased percent million compared percent million compared reflecting strong growth core brands across geographic species areas led higher sales companion animal products products serving us cattle market including nuflor vaccine business led sales growth increased net sales also due part better product supply us scheringplough expects growth rate moderate due increased competition including introduction generic products table contents costs expenses equity income summary costs expenses equity income years ended december follows incre e decr ease dollars millions gross margin selling general administrative sga research development rd incomeexpense net nm nm special charges nm nm equity income cholesterol joint venture nm nm nm meaningful percentage substantially sales cholesterol products included scheringploughs net sales results sales reflected equity income cholesterol joint venture addition due virtual nature joint venture scheringplough incurs substantial selling general administrative expenses captured equity income included scheringploughs statements consolidated operations result scheringploughs gross margin ratios sga expenses rd expenses percentage net sales reflect benefit impact joint ventures operating results gross margin despite negative impacts cost sales costs resulting scheringploughs actions streamline manufacturing operations gross margin increased percent percent improvement gross margin primarily due increased sales higher margin products process improvements within scheringploughs supply chain including cost savings manufacturing streamlining activities completed cost sales included charges totaling million associated schering ploughs actions streamline manufacturing operations offset savings approximately million result actions see note special charges manufacturing streamlining item financial statements supplemental data additional information gross margin increased percent percent primarily due supply chain process improvements increased sales highermargin products favorable impact foreign exchange partly offset higher royalties related bayer products beginning september royalties integrilin selling general administrative selling general administrative expenses sga increased percent billion compared reflecting ongoing investments emerging markets field support product launches well higher promotional spending sga expenses increased percent billion compared billion increase primarily due addition fourth quarter bayer sales representatives increased selling expenses europe support continued launch vytorin zetia increased promotional spending primarily nasonex asmanex products agreement bayer research development research development rd spending increased percent billion compared period rd spending increased percent billion compared period increase due higher costs associated clinical trials well building greater breadth capacity support scheringploughs progressing pipeline increase partially due million charge third quarter resulting scheringploughs exercise rights develop commercialize golimumab rd spending included million charge conjunction license toyama table contents chemical company ltd garenoxacin generally changes rd spending reflect timing scheringploughs funding internal research efforts research collaborations various partners discover develop steady flow innovative products maximize scheringploughs chances successful development new products scheringplough began development excellence initiative build talent critical mass create uniform level excellence deliver highpriority programs within rd scheringplough began global clinical harmonization program maximize globalize quality clinical trial execution pharmacovigilance regulatory processes incomeexpense net scheringplough income net million compared expense net million million respectively due higher interest rates larger overall balances cash equivalents shortterm investments special charges manufacturing streamlining manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamline global supply chain enhance schering ploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new jersey total actions resulted elimination positions scheringplough expects actions yield annualized cost savings approximately million special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed charges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december accrued liability balance december expected paid first quarter scheringplough expect incur material additional charges related manufacturing streamlining actions announced table contents special charge activities special charges incurred follows dollars millions litigation charges employee termination costs asset impairment charges litigation charges litigation reserves increased million increase resulted total reserve million massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters representing scheringploughs current estimate resolve matter august scheringplough announced reached agreement us attorneys office district massachusetts us department justice settle massachusetts investigation aggregate amount million plus interest settlement amount relates massachusetts investigation awp investigations litigation ongoing subsequent december scheringplough made payments totaling million related settlement including interest million substantially remaining payments settlement agreement paid remainder see note legal environmental regulatory matters item financial statements supplementary data additional information employee termination costs august scheringplough announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program retired december total cost program approximately million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants million amounts recognized program million million respectively additional amounts expected recognized program termination costs associated verp totaled million million respectively following summarizes activity accounts related employee termination costs employee termination costs dollars millions special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december disbursements special charges liability balance december table contents asset impairment charges year ended december scheringplough recognized asset impairment charges million related primarily consolidation scheringploughs us biotechnology organizations scheringplough recorded asset impairment charges million related primarily shutdown small european research development facility equity income cholesterol joint venture global cholesterol franchise sales include sales vytorin zetia made cholesterol joint venture merck scheringplough totaled billion billion billion respectively sales growth due increase market share sales comparison benefited us launch vytorin second half franchise two products combined captured percent total prescriptions us cholesterol management market based january ims data scheringplough utilizes equity method accounting joint venture sharing income operations based upon percentages vary product sales level country scheringploughs allocation joint venture income increased milestones earned merck scheringplough partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details set annual basis italy contractual amount included profit sharing calculation reimbursed amounts equal partners physician details multiplied contractual fixed fee scheringplough reports amounts part equity income cholesterol joint venture amounts represent specific incremental identifiable costs scheringploughs detailing cholesterol products markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners additional information regarding joint venture merck also included note equity income cholesterol joint venture item financial statements supplementary data equity income cholesterol joint venture totaled billion million million respectively increase equity income compared reflecting continued strong sales vytorin zetia equity income comparison benefited us launch vytorin second half scheringplough recognized milestones merck million million respectively million milestone related certain european approvals vytorin ezetimibesimvastatin million milestone related approval ezetimibesimvastatin mexico certain conditions specified joint venture agreements merck scheringplough could earn additional milestones totaling million noted scheringplough incurs substantial selling general administrative costs reflected equity income cholesterol joint venture instead included overall cost structure scheringplough provision income taxes tax expense million million million respectively tax provisions include benefit related us operating losses scheringplough established valuation allowance net us deferred tax assets including benefit us operating losses management concluded likely benefit us net deferred tax assets realized december scheringplough continues maintain valuation allowance table contents us deferred tax assets scheringplough expects report us net operating loss nol carryforward billion tax return year ended december us nol carryforward could materially reduced examination scheringploughs income tax returns internal revenue service irs scheringplough generated approximately million us operating losses however due differences financial tax reporting expected nol generated us tax return less us operating loss year scheringplough expects continue generate us operating losses however us nol subject differences financial tax reporting income tax provision primarily relates foreign taxes tax provision includes benefit million related irs notice issued august resulted reduction previously accrued tax liability attributable repatriations american jobs creation act ajca tax provision includes million charge related intended ajca repatriation took place irs examining scheringploughs federal income tax returns process completing examination scheringplough anticipates examination completed end finalization irs audit may result adjustments scheringploughs accruals tax contingencies us nols reported schering ploughs income tax returns scheringploughs tax reserves reflect best estimate probable tax liability however reasonably possible ultimate resolution tax matters may materially greater less amount accrued july fasb issued fasb interpretation fin accounting uncertainty income taxes fin prescribes detailed guidance financial statement recognition measurement disclosure uncertain tax positions recognized enterprises financial statements accordance fasb statement accounting income taxes scheringplough required apply provisions interpretation beginning january provisions fin applied existing uncertain income tax positions effective date upon implementation fin cumulative effect applying provisions interpretation reported adjustment opening balance schering ploughs retained earnings although scheringplough still evaluating potential impact fin expects decrease opening retained earnings january million million corresponding increase appropriate tax liability accounts upon adoption interpretation net incomeloss available common shareholders scheringplough net incomeloss available common shareholders billion million million respectively net income available common shareholders included deduction preferred stock dividends million period related issuance percent mandatory convertible preferred stock august net loss available common shareholders included deduction preferred stock dividends million net incomeloss available common shareholders also included special charges manufacturing streamlining costs approximately million million million respectively see note special charges manufacturing streamlining item financial statements supplementary data additional information addition net income available common shareholders included income item million resulting cumulative effect change accounting principle net tax related implementation sfas r sharebased compensation liquidity financial resources discussion cash flow th e ears en ded de ce mber dollars millions cash flow operating activities cash flow investing activities cash flow financing activities table contents operating activities net cash provided operating activities billion increase billion compared increase primarily resulted higher net income timing operating cash payments receipts disclosed note legal environment regulatory matters scheringplough reached agreement us attorneys office district massachusetts us department justice settle massachusetts investigation aggregate amount million plus interest subsequent december scheringplough made payments totaling million related settlement including interest million substantially remaining payments settlement agreement paid remainder operating activities generated million cash compared use million increase primarily due higher net income timing payments special charges related litigation partially offset increase accounts receivable due sales growth payments approximately million tax authorities tax liabilities related repatriation foreign earnings ajca tax payments million related settlement certain tax contingencies tax years tax charges related ajca expensed operating cash flow favorably impacted us tax refund million result loss carryback however cash flow unfavorably impacted million payment us government tax deficiency related certain transactions tax years payment million settlement agreement us attorneys office eastern district pennsylvania investing activities net cash used investing activities billion primarily related net purchases shortterm investments billion previously invested cash equivalents million capital expenditures net cash used investing activities million primarily related million capital expenditures purchase intangible assets million partially offset proceeds sales property equipment million net reduction shortterm investments million net cash used investing activities million included capital expenditures million net purchases investments million partially offset cash proceeds million transfer license rights million dispositions property equipment financing activities net cash used financing activities billion million respectively uses cash financing activities include payment dividends common preferred shares million million respectively repayment billion bank debt shortterm commercial borrowings billion shortterm commercial paper borrowings uses cash financing activities partially offset proceeds million bank debt incurred foreign subsidiary related funding portion repatriations ajca bank debt fully repaid net cash provided financing activities reflected proceeds billion preferred stock issuance million increase shortterm borrowings partially offset payment dividends common preferred shares million discussion cash flows scheringplough moving forward additional investments enhance infrastructure business currently process building us pharmaceutical sciences center new jersey capital expenditures approximately million made related center additional capital expenditures approximately million expected next three years center allow scheringplough streamline integrate drug development process products moved drug discovery pipeline market additional related expenditures upgrade equipment staffing center table contents us operations generated negative cash flow us operations cash needs excess cash generated us us operations must fund dividend payments majority research development costs us capital expenditures expected us operation also generate negative cash flow total cash cash equivalents shortterm investments less total debt approximately billion december cash generated operations available cash short term investments expected provide scheringplough ability fund cash needs intermediate term percent mandatory convertible preferred stock august scheringplough issued percent mandatory convertible preferred stock received net proceeds billion deducting commissions discounts underwriting expenses proceeds used reduce shortterm commercial paper borrowings pay tax litigation settlement amounts litigation costs fund operating expenses capital expenditures preferred stock issued scheringploughs billion shelf registration preferred share automatically convert common shares scheringplough depending average closing price scheringploughs common shares period immediately preceding mandatory conversion date september defined prospectus see note shareholders equity item financial statements supplementary data additional information conversion preferred shares trigger cash payment scheringplough december million remains registered unissued shelf registration borrowings credit facilities november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due proceeds offering billion used general corporate purposes including repaying commercial paper outstanding us upon issuance notes rated moodys investors service moodys credit watch negative implications standard poors sp interest rates payable notes subject adjustment rating assigned notes either moodys sp downgraded respectively interest rate payable series notes would increase see note shortterm borrowings longterm debt commitments item financial statements supplementary data additional information july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december therefore december interest rate payable notes due increased percent percent interest rate payable notes due increased percent percent adjustment interest rate payable notes increased scheringploughs interest expense approximately million annually interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade either moodys sp respectively notes subsequently rated baa moodys bbb sp scheringplough billion credit facility syndicate banks facility matures may requires scheringplough maintain total debt total capital ratio percent met december credit line available general corporate purposes considered support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december million drawn facility whollyowned international subsidiary purposes funding repatriations ajca borrowing amount fully repaid december borrowings outstanding facility addition credit facility scheringplough entered million credit facility fourth quarter purposes funding repatriations ajca december entire amount drawn whollyowned international subsidiary fund repatriations facility paid full terminated table contents december shortterm borrowings including credit facilities mentioned totaled million billion respectively including outstanding commercial paper million million respectively weightedaverage interest rate shortterm borrowings december percent percent respectively credit ratings scheringploughs current unsecured senior credit ratings outlook follows senior unsecured credit ratings l ongterm shortterm outlook moodys investors service baa p positive standard poors stable fitch ratings f stable shortterm ratings discussed significantly affected scheringploughs ability issue roll outstanding commercial paper borrowings time however scheringplough believes ability commercial paper issuers scheringplough one shortterm credit ratings p moodys sp andor f fitch issue roll outstanding commercial paper times less companies higher shortterm credit ratings addition total amount commercial paper capacity available issuers typically less higherrated companies scheringploughs sizable lines credit commercial banks well cash shortterm investments held us international subsidiaries serve alternative sources liquidity support commercial paper program scheringploughs credit ratings could decline current levels impact decline could reduce availability commercial paper borrowing would increase interest rate scheringploughs short longterm debt discussed scheringplough believes existing cash shortterm investments cash generated operations allow scheringplough fund cash needs intermediate term contractual obligations offbalance sheet arrangements scheringplough various contractual obligations reported liabilities consolidated balance sheets others required recognized liabilities certain purchase commitments executory contracts following table summarizes payments due period scheringploughs known contractual obligations december paymen ts due p eriod less total year years years years dollars millions shortterm borrowings current portion longterm debt longterm debt obligations operating lease obligations purchase obligations advertising contracts research contracts capital expenditure commitments purchase obligations deferred compensation plan obligations obligations total longterm debt obligations include million aggregate principal amount percent senior unsecured notes due million aggregate principal amount percent senior unsecured notes due excludes interest obligations see note shortterm borrowings longterm debt table contents commitments item financial statements supplementary data additional information research contracts include potential milestone payments made since payments contingent occurrence certain events table also excludes research contracts cancelable scheringplough without penalty purchase obligations consist cancelable noncancelable inventory expense items caption includes obligations based undiscounted amounts estimated payments certain scheringploughs pension plans preferred stock dividends contractual obligations regulatory competitive environment scheringplough operates scheringplough subject jurisdiction various national state local regulatory agencies regulations described detail item business regulatory compliance complex regulatory standards including good clinical practices good laboratory practices good manufacturing practices vary jurisdiction constantly evolving regulatory compliance also costly regulatory compliance also impacts timing needed bring new drugs market market drugs new indications failure comply regulations result delays approval drugs seizure recall drugs suspension revocation authority necessary production sale drugs fines civil criminal sanctions regulatory compliance cost compliance failures material impact scheringploughs results operations cash flows financial condition much still unknown science human health every drug benefits risks may balanced societal government pressures constantly shifting demand innovation meet urgent unmet medical needs adversity risk pressures impact regulatory environment market scheringploughs products regulatory compliance pharmacovigilance consent decree since scheringplough working us fda consent decree resolve issues involving scheringploughs compliance current good manufacturing practices cgmp certain manufacturing sites new jersey puerto rico see details note consent decree item financial statements supplementary data terms consent decree scheringplough made payments totaling million end scheringplough completed revalidation programs bulk active pharmaceutical ingredients finished drug products well significant steps cgmp work plan accordance schedules required consent decree scheringplough obtained thirdparty expert certification completion cgmp work plan required decree certification turn subject acceptance fda terms decree provided fda notified scheringplough significant violation fda law regulations decree fiveyear period since decrees entry may scheringplough may petition court decree dissolved fda oppose scheringploughs petition assurance particular date consent decree lifted regulatory inspections scheringplough subject pharmacovigilance reporting requirements many countries jurisdictions including us eu eumember states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert drugs manufacturer governmental agency potential problems table contents pharmacovigilance inspections officials british french medicines agencies conducted request european medicines agency emea cited serious deficiencies reporting processes scheringplough continued work longterm action plan rectify deficiencies provided regular updates emea fourth quarter local uk emea regulatory authorities conducted follow inspection assess scheringploughs implementation action plan first quarter authorities also inspected usbased components scheringploughs pharmacovigilance system inspectors acknowledged progress made since also continued note significant concerns quality systems supporting scheringploughs pharmacovigilance processes similarly follow inspection scheringploughs clinical trial practices uk inspectors identified issues respect scheringploughs management clinical trials related pharmacovigilance practices scheringplough intends continue upgrading skills processes systems clinical practices pharmacovigilance scheringplough remains committed accomplish work invest significant resources area february scheringplough began global clinical harmonization program building clinical excellence trial design execution tracking strengthen scheringploughs scientific compliance rigor global basis scheringplough know action emea national authorities take response inspections possible actions include inspections demands improvements reporting systems criminal sanctions scheringplough andor responsible individuals changes conditions marketing authorizations scheringploughs products regulatory compliance postmarketing surveillance scheringplough engages clinical trial research many countries around world clinical trial research activities must comply stringent regulatory standards subject inspection us eu local country regulatory authorities failure comply current good clinical practices applicable laws regulations quality processes result delays approval clinical trials suspension ongoing clinical trials delays approval marketing authorizations criminal sanctions scheringplough andor responsible individuals changes conditions marketing authorizations scheringploughs products increased costs clinical trials postmarketing surveillance certain marketed drugs competitors within industry raised safety concerns led recalls withdrawals adverse labeling marketed products addition situations raised concerns among prescribers patients relating safety efficacy pharmaceutical products general scheringploughs personnel regular open dialogue fda regulators review product labels materials regular basis new information becomes known following wake recent product withdrawals companies significant safety issues health authorities fda emea pmda japan continued increase focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially us advertising promotion particular directtoconsumer advertising similarly major health authorities including fda emea pmda also increased collaboration amongst especially regard evaluation safety benefitrisk information media attention also increased current environment health authority regulatory action one market safety labeling change may regulatory prescribing marketing implications markets extent previously seen health authorities pmda publicly acknowledged significant backlog workload due resource constraints within agency backlog caused long regulatory review times new indications products including initial approval zetia japan added uncertainty table contents predicting approval timelines markets pmda committed correcting backlog made progress last year expected continue foreseeable future uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect scheringploughs operations effect regulatory approval processes operations predicted scheringplough nevertheless achieved significant number important regulatory approvals since including approvals vytorin clarinex clarinex reditabs clarinex new indications temodar nasonex significant approvals since include asmanex dpi dry powder inhalation us noxafil us eu australia pegintron japan new indications remicade scheringplough also number significant regulatory submissions filed major markets awaiting approval pricing pressures described specifically note legal environmental regulatory matters item financial statements supplementary data pricing sales marketing programs arrangements related business practices scheringplough participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject scheringplough substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs scheringplough also predict whether investigations affect marketing practices sales result could material adverse impact scheringploughs results operations cash flows financial condition business us many scheringploughs pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts us market scheringplough pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs international markets scheringplough operates environment government mandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs since scheringplough unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals us effect operations cash flows reasonably estimated similarly effect operations cash flows decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated medicare scheringplough predict net effect medicare prescription drug benefit markets sales new medicare drug benefit medicare part took effect january offers voluntary prescription drug coverage subsidized medicare million medicare beneficiaries competing private prescription drug plans pdps medicare advantage plans many scheringploughs leading drugs already covered medicare part b eg temodar integrilin intron table contents medicare part b provides payment physician services include prescription drugs administered along physician services manner drugs reimbursed medicare part b may limit scheringploughs ability offer larger price concessions make large price increases drugs scheringplough drugs relatively small portion sales medicare population eg clarinex hepatitis c franchise scheringplough could experience expanded utilization vytorin zetia new drugs schering ploughs rd pipeline greater consequence scheringplough may legislations impact pricing rebates discounts competition market pharmaceutical products competitive scheringploughs operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors new information clinical trials marketed products postmarketing surveillance generic competition scheringploughs products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted outlook scheringplough track actions build longterm high performance build base phase action agenda scheringplough continue make investments support geographical expansion strategy plans make sound promotional investments continue driving growth key brands worldwide scheringplough remains focused controlling overhead spending maintaining rightsized sales force current opportunities us scheringplough currently provide numeric guidance however following outlook may helpful readers assessing future prospects currently us cholesterol lowering market adjusting entry market multiple generic forms competing cholesterol products despite introduction new innovative competing treatments generic versions competing products scheringplough continues anticipate sales vytorin zetia grow decisions government entities managed care groups groups concerning formularies reimbursement policies could negatively impact dollar size andor growth cholesterol management market including vytorin zetia scheringploughs pipeline continues progress expects number patients scheringploughs clinical trials increase substantially scheringplough also continue invest research development focus enhancing infrastructure upgrading processes systems talent result scheringplough expects rd expenses excluding upfront payments grow faster adjusted net sales adjusted net sales defined net sales plus assumed percent global cholesterol joint venture net sales scheringplough believes growth comparison provides useful guideline review outlook rd expenses result scheringploughs actions streamline manufacturing operations scheringplough expects annualized cost savings approximately million gross margin improve accordingly risks described item risk factors could cause actual results differ expectations provided section impact recently issued accounting standards september fasb issued sfas fair value measurements effective calendaryear companies january statement defines fair value establishes framework measuring fair value accordance generally accepted accounting principles expands disclosures fair value measurements statement codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date table contents standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions scheringplough currently assessing potential impacts implementing standard september sec staff issued staff accounting bulletin sab topic n sab financial statements considering effects prior year misstatements quantifying misstatements current year financial statements effective calendaryear companies december sab provides guidance prior year misstatements taken consideration quantifying misstatements current year financial statements purposes determining whether financial statements materially misstated guidance companies take account effect misstatement current year balance sheet well impact upon current year income statement assessing materiality current year misstatement current year misstatement quantified guidance sab topic financial statements materiality sab applied determine whether misstatement material implementation sab impact scheringploughs financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxes fin prescribes detailed guidance financial statement recognition measurement disclosure uncertain tax positions recognized enterprises financial statements accordance fasb statement accounting income taxes scheringplough required apply provisions interpretation beginning january provisions fin applied existing uncertain income tax positions effective date upon implementation fin cumulative effect applying provisions interpretation reported adjustment opening balance retained earnings although scheringplough still evaluating potential impact fin upon adoption fin expects decrease opening retained earnings january million million corresponding increase accrued liability accounts upon adoption interpretation critical accounting policies estimates following accounting policies estimates considered significant changes certain judgments assumptions inherent policies could affect scheringploughs financial statements revenue recognition rebates discounts returns provision income taxes impairment intangible assets property accounting pensions postretirement benefit plans accounting legal regulatory matters revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business table contents recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process revenue recognition new products based specific facts circumstances including estimated acceptance rates established products similar marketing characteristics absent ability make reliable estimates rebates discounts returns scheringplough would defer revenue recognition product discounts granted based terms arrangements wholesalers managedcare organizations government purchasers certain market conditions rebates estimated based sales contract terms historical experience trend analysis projected market conditions various markets served scheringplough evaluates market conditions products groups products primarily analysis thirdparty demand market research data well internally generated information data information provided purchasers obtained third parties subject inherent limitations accuracy validity sales returns estimated recorded based historical sales returns information analysis recent wholesale purchase information consideration stocking levels wholesalers forecasted demand amounts products exhibit unusual sales return patterns due dating competition including expected generic introductions marketing matters specifically investigated analyzed part formulation return reserves scheringploughs agreements major us pharmaceutical wholesalers address number commercial issues product returns timing payment processing chargebacks quantity inventory held wholesalers respect quantity inventory held wholesalers agreements provide financial disincentive wholesalers acquire quantities product excess necessary meet current patient demand use agreements scheringplough expects avoid situations scheringploughs shipments product reflective current demand rebates discounts returns scheringploughs rebate accruals federal state governmental programs including medicaid medicare part december million million respectively commercial discounts returns rebate accruals us december million million respectively accruals established period related revenue recognized resulting reduction sales establishment liabilities included total current liabilities case returns receivable adjustments allowance provided accounts receivable case governmental rebate programs scheringploughs payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy scheringploughs obligations additional information governmental inquiries focused part calculation rebates contained note legal environmental regulatory matters item financial statements supplementary data addition possible result governmental challenges changes interpretive guidance actual rebates could materially exceed amounts accrued table contents following summarizes activity accounts related accrued rebates sales returns discounts year ended year ended december december dollars millions accrued rebatesreturnsdiscounts beginning period provision rebates adjustment prioryear estimates payments provision returns adjustment prioryear estimates returns provision discounts adjustment prioryear estimates discounts granted accrued rebatesreturnsdiscounts end period year ended december adjustment prioryear estimates rebates includes million resulting reversal accrued rebate amounts recorded tricare retail pharmacy program august us federal court appeals ruled pharmaceutical manufacturers obligated pay formulating recording accruals management utilizes assumptions estimates include historical experience wholesaler data projection market conditions estimated lag time sale payment rebate utilization estimates forecasted product demand amounts discussed critical accounting policy entitled revenue recognition part review accruals management performs sensitivity analysis considers differing assumptions subject judgment rebate accrual calculation based upon scheringploughs sensitivity analysis reasonably possible changes assumptions related rebate accruals federal state governmental programs could favorably unfavorably impact net sales income taxes approximately million provision income taxes december taxes provided approximately billion earnings international subsidiaries scheringplough considers earnings indefinitely reinvested international subsidiaries scheringplough believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions taxing authorities scheringplough accrues liabilities identified tax contingencies result tax positions taken could challenged tax authorities scheringploughs tax reserves reflect scheringploughs best estimate probable tax liability however reasonably possible ultimate resolution tax matters may materially greater less amount accrued scheringplough adopt fin accounting uncertainty income taxes january see impact recently issued accounting standards discussed additional table contents information regarding expected impacts scheringploughs financial statements implementation fin scheringploughs potential tax exposures result varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property although scheringploughs cross border arrangements affiliates based upon internationally accepted standards tax authorities various jurisdictions may disagree subsequently challenge amount profits taxed country scheringplough records valuation allowance reduce deferred tax assets amount likely realized scheringplough considered ongoing prudent feasible tax planning strategies assessing need valuation allowance event scheringplough determine would able realize additional portion net deferred tax assets adjustment valuation allowance would increase income period determination made likewise scheringplough subsequently determine would able realize additional portion remaining net deferred tax asset future adjustment deferred tax asset would charged income period determination made impairment intangible assets property intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled million december annual amortization expense next five years estimated approximately million per year based intangible assets recorded december value assets subject continuing scientific medical marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment certain scheringploughs manufacturing sites operate capacity overall costs operating manufacturing sites significantly increased due consent decree compliance activities scheringploughs manufacturing cost base relatively fixed actions part management significantly reduce scheringploughs manufacturing infrastructure involve complex issues result shifting products manufacturing plants take many years due construction regulatory requirements including revalidation registration requirements management continues review carrying value certain manufacturing assets indications impairment future events decisions may lead additional asset impairments andor related costs accounting pension postretirement benefit plans pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions scheringplough assesses pension post retirement benefit plan assumptions regular basis evaluating assumptions scheringplough considers many factors including evaluation discount rate expected rate return plan assets healthcare cost trend rate retirement age assumption scheringploughs historical assumptions compared actual results analysis current market conditions asset allocations see note retirement plans postretirement benefits item financial statements supplementary data additional information discount rates used pension postretirement benefit plan calculations evaluated annually modified reflect prevailing market rates measurement date highquality fixed income debt instrument portfolio would provide future cash flows needed pay benefits included benefit obligations come due countries debt instruments thinly traded estimates based available market rates table contents actuarial assumptions based upon managements best estimates judgment assumptions held constant increase basis points discount rate would estimated favorable impact million net pension postretirement benefit cost increase basis points expected rate return assumption would estimated favorable impact million net pension postretirement benefit cost assumptions held constant decrease basis points discount rate would estimated unfavorable impact million net pension postretirement benefit cost decreased basis points expected rate return assumption would estimated unfavorable impact million net pension postretirement benefit cost expected rates return pension postretirement benefit plans represent average rates return earned plan assets period benefits included benefit obligation paid developing expected rate return scheringplough determines expected returns major asset classes principally equities fixed income real estate return expectations asset classes based assumptions economic growth inflation supported longterm historical data well scheringploughs actual experience return plan assets expected portfolio performance also reflects contribution active management appropriate unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions expected returns based primarily calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ scheringploughs expected returns majority assets realized marketrelated value assets ratably fiveyear period total unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees targeted investment portfolio scheringploughs us pension plan allocated percent equities percent fixed income investments percent real estate targeted investment portfolio scheringploughs us postretirement benefit plans allocated percent equities percent fixed income investments portfolios equity weightings consistent longterm nature plans benefit obligations nonus pension plans targeted investment portfolio varies based duration pension liabilities local governmental rules regulations substantially investments equities fixed income valued based quoted public market values investments real estate valued based periodic appraisals september fasb issued sfas employers accounting defined benefit pension postretirement plans amendment fasb statements r effective december scheringplough accounts retirement postretirement benefit plans accordance sfas shareholders equity december reduced approximately percent upon adoption sfas see note retirement plans postretirement benefits item financial statements supplemental data additional information sfas allows extended adoption date yearend measurement date requirement allowed statement currently majority scheringploughs retirement postretirement benefit plans assets liabilities measured december remaining plans measurement dates yearend scheringplough anticipates adopting yearend measurement date effective december scheringplough expect material impact financial statements upon adoption accounting legal regulatory matters management judgments estimates required accounting legal regulatory matters ongoing basis including insurance coverages scheringplough reviews status claims investigations legal proceedings ongoing basis time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution table contents claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs results operations cash flows financial condition market risk disclosure scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk scheringplough subsidiaries countries sales outside us accounted approximately percent global sales virtually sales denominated currencies local country scheringploughs reported profits cash flows exposed changing exchange rates date management deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact scheringploughs international operations widespread addition point time scheringploughs international subsidiaries hold financial assets liabilities denominated currencies us dollars financial assets liabilities consist primarily shortterm thirdparty intercompany receivables payables changes exchange rates affect translated value financial assets liabilities gains losses arise translation affect net income occasion scheringplough used derivatives hedge specific foreign currency exposures however derivative transactions material interest rate equity price risk financial assets exposed changes interest rates andor equity prices primarily cash equivalents shortterm investments debt equity securities held nonqualified trusts employee benefits assets totaled billion december cash equivalents shortterm investments percent decrease interest rates would decrease interest income approximately million securities held nonqualified trusts due longterm nature liabilities trust assets fund scheringploughs exposure market risk deemed low financial obligations exposed variability interest rates primarily shortterm borrowings scheringplough currently maintains investment portfolio shortterm investment instruments excess amount borrowings accordingly scheringplough mitigated exposure changes interest rates relating financial obligations scheringplough longterm debt outstanding percent decrease interest rates would increase fair value debt approximately million however schering plough currently expect refund debt disclosure notice cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time scheringplough may contain forwardlooking statements within meaning private securities litigation reform act forward table contents looking statements relate strictly historical current facts based current expectations forecasts future events identify forward looking statements use words anticipate believe could estimate expect forecast project intend plan potential similar words terms particular forward looking statements include statements relating future actions ability access capital markets prospective products product approvals timing conditions regulatory approvals patent intellectual property protection future performance results current anticipated products sales efforts research development programs estimates rebates discounts returns expenses programs reduce expenses cost savings reductions work force outcome contingencies litigation investigations growth strategy financial results forwardlooking statements publications may turn wrong guarantees scheringploughs financial operational performance performance scheringploughs stock scheringplough assume obligation update forwardlooking statement many factors could cause actual results differ materially scheringploughs forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known although possible predict identify factors refer item risk factors report incorporate herein reference identification important factors respect risks uncertainties item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis table contents item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements report independent registered public accounting firm table contents scheringplough corporation subsidiaries statements consolidated operations amounts millions except per share figures ears end ed de c e mber net sales cost sales selling general administrative research development incomeexpense net special charges equity income cholesterol joint venture incomeloss income taxes income tax expense net income cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss preferred stock dividends net incomeloss available common shareholders diluted earningsloss per common share earnings available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax diluted earningsloss per common share basic earningsloss per common share earnings available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle basic earningsloss per common share dividends per common share accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows amounts millions years e nded de ce mber operating activities net incomeloss cumulative effect change accounting principle net tax net income cumulative effect change accounting principle net tax adjustments reconcile net incomeloss net cash provided byused operating activities payments us taxing authorities tax refunds us loss carryback special charges depreciation amortization accrued sharebased compensation changes assets liabilities accounts receivable inventories prepaid expenses assets accounts payable liabilities income taxes payable net cash provided used operating activities investing activities capital expenditures dispositions property equipment proceeds transfer license purchases investments maturity investments net net cash used investing activities financing activities cash dividends paid common shareholders cash dividends paid preferred shareholders proceeds preferred stock issuance net shortterm borrowings payments shortterm borrowings reductions longterm debt stock options exercised net net cash used provided financing activities effect exchange rates cash cash equivalents net decrease increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental disclosure cash paid interest net amounts capitalized cash paid refunded income taxes see note accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets amounts millions except per share figures ec ember assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt us foreign state income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt deferred income taxes longterm liabilities total longterm liabilities commitments contingent liabilities note shareholders equity mandatory convertible preferred shares par value issued per share face value common shares authorized shares par value issued paidin capital retained earnings accumulated comprehensive loss total less treasury shares cost total shareholders equity total liabilities shareholders equity accompanying notes integral part consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity amounts millions ccumulated mandatory total convertible compre share preferred common paidin retained treasury hensive holders shares shares capital earnings shares loss equity balance january comprehensive incomeloss net loss foreign currency translation minimum pension liability net tax accordance sfas unrealized gain investments available sale net tax total comprehensive loss issuance preferred stock cash dividends common shares dividends preferred shares stock incentive plans balance december comprehensive incomeloss net income foreign currency translation minimum pension liability net tax accordance sfas total comprehensive income cash dividends common shares dividends preferred shares stock incentive plans balance december comprehensive income net income foreign currency translation minimum pension liability net tax accordance sfas unrealized gain investments available sale net tax total comprehensive income cash dividends paid common shares dividends preferred shares accrued dividends common shares adjustment pension otherpostretirement liabilities upon adoption sfas net tax stock incentive plans balance december accompanying notes int egra l p art c olidated f cial st em e nts table contents scheringplough corporation subsidiaries notes consolidated financial statements summary significant accounting policies overview scheringplough discovers develops manufactures markets medical therapies treatments enhance human health scheringplough also markets leading consumer brands overthecounter otc foot care sun care markets operates global animal health business principles consolidation consolidated financial statements include scheringplough corporation subsidiaries scheringplough intercompany balances transactions eliminated use estimates preparation financial statements conformity generally accepted accounting principles requires management make estimates use assumptions affect certain reported amounts disclosures actual amounts may differ equity method accounting scheringplough accounts share activity merckscheringplough cholesterol joint venture partnership joint venture merck co inc merck using equity method accounting scheringplough significant influence joint ventures operating financial policies accordingly scheringploughs net sales include sales joint venture scheringploughs share earnings joint venture included consolidated net incomeloss equity income cholesterol joint venture included profit prescription pharmaceutical segment revenue sales vytorin zetia recognized joint venture title risk loss passed customer equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck see note equity income cholesterol joint venture information regarding joint venture cash cash equivalents cash cash equivalents include operating cash highly liquid investments original maturities three months less shortterm investments shortterm investments carried fair value classified availableforsale investments consist time deposits certificates deposit commercial paper maturities less year inventories inventories valued lower cost market cost determined using lastin firstout lifo method substantial portion inventories located us cost inventories determined firstin firstout method fifo depreciation property equipment depreciation provided estimated useful lives properties generally use straightline method table contents notes consolidated financial statements continued useful lives property generally follows asset category ears buildings building improvements equipment scheringplough reviews carrying value property equipment indications impairment accordance statement financial accounting standard sfas accounting impairment disposal longlived assets depreciation expense including accelerated depreciation related manufacturing streamlining million million million million respectively foreign currency translation net assets scheringploughs international subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included comprehensive income loss remaining international subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation account transactional exchange gains losses included income revenue recognition scheringploughs pharmaceutical products sold direct purchasers include wholesalers retailers certain health maintenance organizations price discounts rebates sales paid federal state agencies indirect purchasers market participants managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers scheringplough recognizes revenue title risk loss pass purchaser reliable estimates following determined commercial discount rebate arrangements ii rebate obligations certain federal state governmental programs iii sales returns normal course business recognizing revenue scheringplough estimates records applicable commercial governmental discounts rebates well sales returns expected granted made products sold period amounts deducted sales period reliable estimates items made scheringplough defers recognition revenue estimates recorded prior periods reevaluated part process earnings per common share diluted earningsloss per common share computed dividing net incomeloss available common shareholders sum weighted average number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options dilutive effect shares issuable upon conversion schering ploughs mandatory convertible preferred stock table contents notes consolidated financial statements continued basic earningsloss per common share computed dividing net incomeloss available common shareholders weighted average number common shares outstanding goodwill intangible assets sfas goodwill intangible assets requires intangible assets acquired either individually group assets initially recognized measured based fair value intangible finite life amortized useful life intangible indefinite life including goodwill amortized scheringplough evaluates goodwill impairment using fairvaluebased test goodwill determined impaired written estimated fair value scheringploughs goodwill primarily related animal health business assets included assets capitalized software million million december respectively amortization expense million million million respectively income taxes deferred income taxes recognized future tax effects temporary differences financial income tax reporting basis scheringploughs assets liabilities based enacted tax laws rates accounting sharebased compensation prior january scheringplough accounted stockbased compensation arrangements using intrinsic value method sharebased employee compensation cost reflected net incomeloss scheringploughs deferred stock units performance plans stock options granted plans exercise price equal market value underlying common stock date grant effective january scheringplough accounts sharebased compensation accordance fasb statement financial accounting standard revised share based payment sfas r see note sharebased compensation additional information impact recently issued accounting pronouncements september fasb issued sfas fair value measurements effective calendar year companies january statement defines fair value establishes framework measuring fair value accordance generally accepted accounting principles expands disclosures fair value measurements statement codifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date standard clarifies principle fair value based assumptions market participants would use pricing asset liability establishes fair value hierarchy prioritizes information used develop assumptions scheringplough currently assessing potential impacts implementing standard september sec staff issued staff accounting bulletin sab topic n sab financial statements considering effects prior year misstatements quantifying misstatements current year financial statements effective calendar year companies december sab provides guidance prior year misstatements taken consideration quantifying misstatements current year financial statements purposes determining whether financial statements materially misstated guidance companies take account effect misstatement current year balance sheet well impact upon current year income statement assessing materiality current year misstatement current year misstatement quantified guidance table contents notes consolidated financial statements continued sab topic financial statements materiality sab applied determine whether misstatement material implementation sab impact scheringploughs financial statements july fasb issued fasb interpretation fin accounting uncertainty income taxes fin prescribes detailed guidance financial statement recognition measurement disclosure uncertain tax positions recognized enterprises financial statements accordance fasb statement accounting income taxes scheringplough required apply provisions interpretation beginning january provisions fin applied existing uncertain income tax positions effective date upon implementation fin cumulative effect applying provisions interpretation reported adjustment opening balance retained earnings see note income taxes additional information regarding expected impacts adoption fin scheringploughs financial statements special charges manufacturing streamlining manufacturing streamlining scheringplough implemented changes manufacturing operations puerto rico new jersey streamlined global supply chain enhanced scheringploughs longterm competitiveness changes resulted phaseout closure scheringploughs manufacturing operations manati puerto rico additional workforce reductions las piedras puerto rico new jersey total actions resulted elimination positions special charges special charges related changes scheringploughs manufacturing operations totaled million charges consisted approximately million severance million fixed asset impairments cost sales included cost sales approximately million consisting million accelerated depreciation million inventory writeoffs million charges related closure scheringploughs manufacturing facilities manati puerto rico following table summarizes activities reflected consolidated financial statements related changes scheringploughs manufacturing operations completed charges included special total cash noncash accrued cost sales charges charges payments charges liability dollars millions accrued liability january severance asset impairments accelerated depreciation inventory writeoffs total accrued liability december table contents notes consolidated financial statements continued accrued liability balance december expected paid first quarter scheringplough expect incur material additional charges related manufacturing streamlining actions announced special charges activity special charges incurred follows dollars millions litigation charges employee termination costs asset impairment related charges litigation charges litigation reserves increased million resulting total reserve approximately million massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters august scheringplough announced reached agreement us attorneys office district massachusetts us department justice settle massachusetts investigation aggregate amount million plus interest settlement amount relates massachusetts investigation awp investigations litigation ongoing remaining reserve adequate cover matters subsequent december scheringplough made payments totaling million related massachusetts settlement including interest million scheringplough expects pay remaining payments next several quarters see note legal environmental regulatory matters additional information employee termination costs august scheringplough announced global workforce reduction initiative first phase initiative voluntary early retirement program verp us program eligible employees us december elect early retirement receive enhanced retirement benefit approximately employees elected retire program retired december total cost program approximately million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants million amounts recognized program million million respectively employee termination costs associated verp totaled million million respectively table contents notes consolidated financial statements continued following summarizes activity accounts related employee termination costs employee termination costs dollars millions special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december special charges incurred credit retirement benefit plan liability disbursements special charges liability balance december disbursements special charges liability balance december asset impairment charges year ended december scheringplough recognized asset impairment charges million related primarily consolidation scheringploughs us biotechnology organizations year ended december scheringplough recognized asset impairment charges million based discounted cash flows charges million related primarily shutdown small european research development facility equity income cholesterol joint venture may scheringplough merck co inc merck entered two separate sets agreements jointly develop market certain products us including two cholesterollowering drugs allergyasthma drug december cholesterol agreements expanded include countries world except japan general companies agreed collaborative activities agreements would operate virtual joint venture maximum degree possible relying respective infrastructures two companies agreements generally provide equal sharing development costs copromotion approved products company cholesterol agreements provide scheringplough merck jointly develop ezetimibe marketed zetia us asia ezetrol europe oncedaily monotherapy ii coadministration statin drug iii oncedaily fixedcombination tablet ezetimibe simvastatin zocor mercks cholesterolmodifying medicine combination medication ezetimibesimvastatin marketed vytorin us inegy many international countries zetiaezetrol ezetimibe vytorininegy combination ezetimibesimvastatin approved use us launched several international markets scheringplough utilizes equity method accounting recording share activity merckscheringplough cholesterol joint venture scheringploughs net sales include sales joint table contents notes consolidated financial statements continued venture cholesterol joint venture agreements provide sharing operating income generated joint venture based upon percentages vary product sales level country us market scheringplough receives greater share profits first million annual zetia sales million annual zetia sales merck scheringplough partners generally share profits equally scheringploughs allocation joint venture income increased milestones recognized either partners share joint ventures income operations subject reduction partner fails perform specified minimum number physician details particular country partners agree annually minimum number physician details country partners bear costs general sales forces commercial overhead marketing joint venture products around world us canada puerto rico cholesterol agreements provide reimbursement partner physician details set annual basis italy contractual amount included profit sharing calculation reimbursed us canada puerto rico amount equal partners physician details multiplied contractual fixed fee scheringplough reports amounts part equity income cholesterol joint venture amounts represent reimbursement specific incremental identifiable costs scheringploughs detailing cholesterol product markets addition amounts reflective scheringploughs sales effort related joint venture scheringploughs sales force related costs associated joint venture generally estimated higher year ended december scheringplough recognized milestones million milestones related certain european approvals vytorin ezetimibesimvastatin scheringplough recognized milestone million related approval ezetimibesimvastatin mexico certain conditions specified joint venture agreements merck scheringplough could earn additional milestones totaling million costs joint venture partners contractually share portion manufacturing costs specifically identified promotion costs including directtoconsumer advertising direct identifiable outofpocket promotion agreed upon costs specific services market support market research market expansion specialty sales force physician education programs certain specified research development expenses generally shared equally partners following information provides summary components scheringploughs equity income cholesterol joint venture year ended december dollars millions scheringploughs share net income including milestones respectively contractual amounts physician details elimination intercompany profit net total equity income cholesterol joint venture equity income joint venture excludes profit arising transactions scheringplough joint venture time underlying profit realized joint venture transaction party scheringplough merck due virtual nature cholesterol joint venture scheringplough incurs substantial costs selling general administrative costs reflected equity income borne overall cost structure scheringplough costs reported respective line items statements consolidated operations separately identifiable cholesterol agreements provide table contents notes consolidated financial statements continued jointly owned facilities products resulting joint venture manufactured facilities owned either scheringplough merck allergyasthma agreements provide joint development marketing partners oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january merckscheringplough respiratory joint venture reported results phase iii clinical trials fixedcombination tablet containing claritin singulair phase iii study demonstrate sufficient added benefits treatment seasonal allergic rhinitis although claritin singulair combination tablet approval country phase iii clinical development ongoing sharebased compensation prior january scheringplough accounted stock compensation arrangements using intrinsic value method followed recognition measurement principles apb opinion accounting stock issued employees related interpretations prior stockbased employee compensation cost reflected net income stock options scheringplough plans stock options granted required exercise price equal market value underlying common stock grant date scheringplough adopted statement financial accounting standards revised sharebased payment sfas r effective january sfas r requires companies recognize compensation expense amount equal fair value sharebased payments granted employees scheringplough elected modified prospective transition method therefore adjustments prior periods required result adopting sfas r method provisions sfas r apply awards granted date adoption unrecognized expense awards unvested date adoption based grant date fair value sfas r also amends sfas statement cash flows require excess tax benefits reflected operating cash flows reflected financing cash flows november financial accounting standards board fasb issued fasb staff position fas r transition election related accounting tax effects share based payment awards scheringplough elected adopt transition method provided fasb staff position purposes calculating pool excess tax benefits available absorb tax deficiencies recognized subsequent adoption sfas r second quarter stock incentive plan plan approved scheringploughs shareholders terms plan million schering ploughs authorized common shares may granted stock options awarded deferred stock units officers certain employees scheringplough december december million options deferred stock units remain available future year grants plan scheringplough intends utilize unissued authorized shares satisfy stock option exercises issuance deferred stock units grants issued retirementeligible employees prior adoption sfas r scheringplough recognized compensation costs stated vesting period stock option deferred stock unit acceleration unrecognized compensation costs upon retirement employee upon adoption sfas r scheringplough recognizes compensation costs sharebased grants made january service period earlier employees retirement eligibility date service period award table contents notes consolidated financial statements continued implementation sfas r first quarter scheringplough recognized benefit income million cumulative effect change accounting principle related two longterm compensation plans required accounted liability plans sfas r tax benefits recognized related stockbased compensation related cash flow impacts material scheringplough us net operating loss position stock options stock options granted employees exercise prices equal fair market value scheringploughs stock dates grant stock options plan generally vest three years term seven years certain options granted previous plans vest longer periods ranging three nine years term years compensation costs stock options recognized requisite service period separately vesting portion stock option award expense recognized net estimated forfeitures vesting period options using accelerated method expense recognized approximately million weightedaverage assumptions used blackscholes optionpricing model follows dividend yield volatility riskfree interest rate expected term options years dividend yields based historical dividend yields expected volatilities based historical volatilities scheringploughs common stock riskfree interest rate based us treasury yield curve effect time grant periods corresponding expected life options expected term options represents weighted average period time options granted expected outstanding giving consideration vesting schedules scheringploughs historical exercise patterns amount cash received exercise stock options million million million respectively table contents notes consolidated financial statements continued stockbased compensation prior january determined using intrinsic value method following table provides supplemental information stock based compensation computed sfas dollars millions except per share figures net income available common shareholders reported add back expense included reported net income deferred stock units deduct pro forma expense stock options deferred stock units charged net income available common shareholders accordance sfas pro forma net income available common shareholders using fair value method diluted earnings per common share diluted earnings per common share reported pro forma diluted earnings per common share using fair value method basic earnings per common share basic earnings per common share reported pro forma basic earnings per common share using fair value method summarized information stock options outstanding exercisable december follows utstanding exerc able weighted weighted weighted number average average number average remaining exercise exercise exercise price range options term years price options price thousands thousands weightedaverage fair value stock options granted respectively intrinsic value stock options exercised million million million respectively total fair value options vested million million million respectively december total remaining unrecognized compensation cost related nonvested stock options amounted million amortized weighted average remaining requisite service period years table contents notes consolidated financial statements continued following table summarizes stock option activity december changes year ended current prior plans w eighted number average exercise options price thousands outstanding january granted exercised canceled expired outstanding december exercisable december aggregate intrinsic value stock options outstanding december million aggregate intrinsic value stock options currently exercisable december million intrinsic value stock options calculated based exercise price underlying awards quoted price scheringploughs common stock reporting date following table summarizes nonvested stock option activity december changes year ended current prior plans w eighted number average fair options value thousands nonvested january granted vested forfeited nonvested december deferred stock units fair value deferred stock units determined based number shares granted quoted price scheringploughs common stock date grant deferred stock units generally vest end three years provided employee remains service scheringplough expense recognized straightline basis vesting period deferred stock units payable equivalent number common shares expense recognized million million million respectively table contents notes consolidated financial statements continued summarized information deferred stock units outstanding december follows ou tstanding weighted number average weighted deferred stock remaining average deferred stock unit price range units term years fair value thousands weightedaverage fair value deferred stock units granted respectively total fair value deferred stock units vested million million million respectively december total remaining unrecognized compensation cost related deferred stock units amounted million amortized weightedaverage remaining requisite service period years following table summarizes deferred stock unit activity december changes year ended current prior plans number nonvested weighted deferred stock average units fair value thousands nonvested january granted vested forfeited nonvested december incentive plans scheringplough two compensation plans classified liability plans sfas r ultimate cash payout plans based scheringploughs stock performance compared stock performance peer group upon adoption sfas r january scheringplough recognized cumulative income effect change accounting principle million order recognize liability plans fair value income expense amounts related liability plans based change fair value reporting date fair value plans estimated using lattice valuation model using expected volatility assumptions assumptions appropriate determining fair value amount recognized exclusive impact cumulative effect change accounting principle statements consolidated operations related liability awards expense million december total remaining unrecognized compensation cost related incentive plans amounted million amortized weightedaverage remaining requisite service period years amount vary reporting period based changes fair value table contents notes consolidated financial statements continued incomeexpense net components incomeexpense net follows dollars millions interest cost incurred less amount capitalized construction interest expense interest income foreign exchange losses net total incomeexpense net scheringplough participated healthcare refinancing programs adopted local government fiscal authorities major european market december schering plough transferred million trade accounts receivables owned foreign subsidiary thirdparty financial institution without recourse transfer trade accounts receivable qualified sales accounts receivable sfas accounting transfers servicing financial assets extinguishments liabilities year ended december loss transfer trade accounts receivable immaterial included interest expense cash flows transactions included change accounts receivable operating activities income taxes components consolidated incomeloss income taxes years ended december follows dollars millions united states foreign total incomeloss income taxes including cumulative effect change accounting principle income cholesterol joint venture included table based jurisdiction income earned table contents notes consolidated financial statements continued components income tax expense years ended december follows f ederal st ate f oreign tal dollars millions current deferred total current deferred total current deferred total scheringplough repatriated approximately billion accordance planned repatriation provisions ajca maximum amount foreign earnings qualified effectively reduced tax rate percent fourth quarter scheringplough accrued us federal tax liability approximately million state income tax liability approximately million intended repatriation scheringplough continue use repatriated funds qualified spending scheringploughs tax provision year ended december includes us federal income tax benefit approximately million result irs notice issued august provisions notice resulted reduction previously accrued tax liability attributable american jobs creation act ajca repatriation also reduced us net operating loss nol carried forward subsequent years prior ajca scheringploughs intent indefinitely reinvest unremitted earnings international subsidiaries except amounts repatriated ajca scheringplough maintains intent indefinitely reinvest earnings international subsidiaries scheringplough provided deferred taxes approximately billion undistributed foreign earnings december determining tax liability would arise earnings remitted practicable liability would depend number factors including amount earnings distributed whether us operations generating taxable profits losses due changes tax planning strategies triggered scheringploughs intent repatriate earnings ajca management longer able conclude likely would realize benefit net us deferred tax assets including benefit related us operating losses therefore general scheringplough established valuation allowance net us deferred tax asset december continues maintain valuation allowance net us deferred tax asset december deferred income taxes provided temporary differences financial reporting basis tax basis scheringploughs assets liabilities scheringploughs deferred tax assets result principally recording certain items currently deductible tax purposes net operating loss tax credit carryforwards scheringploughs deferred tax liabilities principally result use accelerated depreciation tax purposes table contents notes consolidated financial statements continued components scheringploughs deferred tax assets liabilities december follows dollars millions deferred tax assets net operating loss nol carryforwards tax credit carryforwards postretirement employee benefits inventory related sales return reserves litigation accruals total deferred tax assets deferred tax liabilities depreciation inventory valuation total deferred tax liabilities deferred tax valuation allowance net deferred tax assets change valuation allowance due decrease deferred tax asset recorded us nol carryforward offset increase deferred tax assets recorded expenses currently nondeductible tax purposes decrease deferred asset recorded us nol carryforward primarily attributable reduction estimated impact irs examination scheringploughs open tax years impact statement operations balance may subsequently increased decreased following resolution examinations deferred tax assets net operating losses tax credit carryforwards principally relate us nols research development rd tax credits us foreign tax credits federal alternative minimum tax amt credit carryforwards december scheringplough approximately billion us nols income tax purposes available offset future us taxable income us nols us operating losses adjusted differences financial tax reporting us nols expire varying amounts unused december scheringplough approximately million rd tax credits carryforwards expire million foreign tax credit carryforwards expire million amt tax credit carryforwards indefinite life us nol carryforward could materially reduced examination scheringploughs income tax returns irs scheringplough reduced deferred tax assets related valuation allowance recorded us nols tax credit carryforwards reflect estimated resolution examinations table contents notes consolidated financial statements continued difference income taxes based us statutory tax rate scheringploughs income tax expense years ending december due following dollars millions income tax expensebenefit us statutory rate increasedecrease taxes resulting lower rates jurisdictions net federal benefit tax repatriated foreign earnings act net credits us operating losses tax benefit recorded permanent differences provision valuation allowance net us deferred tax assets provision tax matters state income tax net income tax effective tax rate lower tax rates jurisdictions net primarily attributable scheringploughs manufacturing subsidiaries puerto rico singapore ireland operate various incentive tax grants begin expire overall income tax expense primarily relates foreign taxes include benefit related us operating losses net consolidated income tax paymentsrefunds exclusive payments related tax examinations litigation discussed million million million respectively january internal revenue service irs completed examination scheringploughs federal income tax returns scheringplough made cash payment third quarter form tax deposit approximately million anticipation settlement tax examination prevent additional irs interest charges payment fully satisfied liability associated tax examination consistent previously recorded reserves irs process completing examination scheringploughs federal income tax returns scheringplough anticipates examination completed end finalization examination may result adjustments scheringploughs accrual tax contingencies us nols reported scheringploughs income tax returns scheringploughs us federal income tax returns remain subject examination scheringplough believes accrual tax contingencies adequate open years based experience interpretations tax law judgments potential actions taxing authorities scheringplough accrues liabilities identified tax contingencies result tax positions taken could challenged tax authorities scheringploughs tax reserves reflect probable outcome identified tax contingencies however reasonably possible ultimate resolution tax matters may materially greater less amount accrued scheringplough adopt fin accounting uncertainty income taxes january see impact recently issued accounting standards note summary significant accounting policies although scheringplough still evaluating potential impact fin expects decrease opening retained earnings january million million corresponding increase appropriate tax liability accounts upon adoption interpretation scheringploughs potential tax exposures result varying application statutes regulations interpretations include exposures intercompany terms cross border arrangements utilization cash held foreign subsidiaries investment us property although scheringploughs cross border arrangements table contents notes consolidated financial statements continued affiliates based upon internationally accepted standards tax authorities various jurisdictions may disagree subsequently challenge amount profits taxed country october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase scheringploughs tax reserves adequate cover abovementioned payments retirement plans postretirement benefits plan descriptions scheringplough defined benefit pension plans covering eligible employees us certain foreign countries us plan benefits normal retirement primarily based upon participants average final earnings years service social security income modified early retirement death disability benefits also available plan benefits become fully vested five years service plan provides continued accrual credited service employees opt postpone retirement remain employed scheringplough reaching normal retirement age nonus pension plans offer benefits competitive local market conditions addition scheringplough provides postretirement medical life insurance benefits primarily eligible us retirees dependents postretirement benefit plans effective december scheringplough accounts retirement plans postretirement benefit plans plans accordance sfas employers accounting defined benefit pension postretirement plans amendment sfas r sfas requires recognition asset overfunded plans liability underfunded plans scheringploughs consolidated balance sheets statement also requires recognition changes funded status plans year changes occur provided sfas requirement measure plans assets liabilities fiscal yearend extended effective years ending december currently majority scheringploughs retirement postretirement benefit plans assets liabilities measured december table contents notes consolidated financial statements continued incremental effects resulting implementation sfas individual line items scheringploughs consolidated balance sheets december follows balance sheets balance sheets amounts prior amounts sfas sfas sfas sfas adjustments adjustments adjustments adjustments assets intangible assets longterm assets including deferred tax asset liabilities accrued compensation longterm liabilities equity accumulated comprehensive loss net tax effects december included scheringploughs accumulated comprehensive loss million million net tax effects costs recognized components net periodic benefit costs pursuant sfas employers accounting pensions sfas employers accounting postretirement benefits pensions components costs december follows postretirement retirement plans benefits actuarial loss prior service costcredit total actuarial losses primarily represent cumulative difference actuarial assumptions actual returns plan assets changes discount rates plans experience total loss amounts net excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amounts accumulated comprehensive loss expected recognized components net periodic costs follows postretirement retirement plans benefits actuarial loss recognition prior service costcredit recognition table contents notes consolidated financial statements continued actuarial assumptions consolidated weighted average assumptions used determine benefit obligations december th er post retirement retirement plans benefits discount rate rate increase future compensation na na assumptions used develop benefit obligations yearend consolidated weighted average assumptions used determine net benefit costs years ended december ther retirement plans postretirement benefits discount rate longterm expected rate return plan assets rate increase future compensation na na na assumptions used determine net periodic benefit costs year established end previous year assumptions used determine benefit obligations established yearend net periodic benefit costs actuarial present value benefit obligations based actuarial assumptions determined annually based evaluation longterm trends well market conditions may impact cost providing retirement benefits longterm expected rates return plan assets derived return assumptions determined major asset classes equities fixed income real estate proportional basis return expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weighted average assumed healthcare cost trend rate used postretirement measurement purposes percent trending percent one percent increase assumed healthcare cost trend rate would increase combined postretirement service interest cost million postretirement benefit obligation million one percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost million postretirement benefit obligation million average retirement age assumed based annual rates retirement experienced scheringplough components net periodic benefit costs net pension postretirement benefit costs totaled million million million respectively table contents notes consolidated financial statements continued components net pension postretirement benefits expense follows ther retirement plans postretirement benefits dollars millions service cost interest cost expected return plan assets amortization net termination benefits settlement net pension postretirement benefit costs accordance fasb staff position accounting disclosure requirements related medicare prescription drug improvement modernization act medicare act scheringplough began accounting effect federal subsidy medicare act third quarter result scheringploughs net postretirement benefits expense reduced million reduction postretirement benefits expense consists reductions service cost interest cost net amortization million million million respectively benefit obligations components changes benefit obligations follows p os tretire ment retirement plans benefits dollars millions benefit obligations beginning year service cost interest cost medicare drug subsidy received participant contributions effects exchange rate changes benefits paid acquisitionsplan transfers actuarial lossesgains including assumption change plan amendments termination benefits curtailment settlement benefit obligations end year benefit obligations overfunded plans benefit obligations underfunded plans table contents notes consolidated financial statements continued funded status balance sheets presentation components changes plan assets follows th er post retirement retirement plans benefits dollars millions fair value plan assets primarily stocks bonds beginning year actual gain loss plan assets employer contributions participant contributions acquisitionsplan transfers effects exchange rate changes settlements benefits paid fair value plan assets end year plan assets overfunded plans plan assets underfunded plans addition plan assets indicated december securities investments million million respectively held nonqualified trust designated provide pension benefits certain underfunded plans accordance sfas december net asset overfunded plans million related scheringploughs retirement plans included longterm assets net liability underfunded plans december totaled million follows retirement postretirement plan benefits dollars millions accrued compensation current longterm liabilities total prior december scheringplough accounted retirement plans postretirement benefit plans accordance sfas r following table reconciliation funded status plans net assetliability december retirement postretirement plan benefits dollars millions benefit obligations excess plan assets post measurement date contributions unrecognized prior service costs unrecognized net actuarial loss net assetliability end year table contents notes consolidated financial statements continued december components net assetliability recorded consolidated balance sheets follows retirement postretirement plans benefits dollars millions prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive loss net assetliability end year december scheringploughs additional minimum pension liability million primarily related domestic retirement plans resulted adjustment accumulated comprehensive loss net tax million december accumulated benefit obligations abo retirement plans million million respectively aggregated accumulated benefit obligations fair values plan assets retirement plans accumulated benefit obligations excess plan assets million million respectively december million million respectively december plan assets fair value asset allocation consolidated retirement plans december target allocation follows pe rce ntage f target plan assets allocation december asset category equity securities debt securities real estate total asset allocation postretirement benefit trusts december target allocation follows pe rce ntage f target plan assets allocation december asset category equity securities debt securities total scheringploughs investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns consistent acceptable level overall portfolio market value risk assets periodically rebalanced back target allocations table contents notes consolidated financial statements continued estimated future benefit payments following benefit payments reflect expected future service appropriate expected paid retirement postretirement plans benefits dollars millions years scheringploughs practice fund qualified pension plans least sufficient amounts meet minimum requirements set forth applicable laws scheringplough expects contribute approximately million retirement plans including approximately million us retirement plan defined contribution plans scheringplough makes contributions defined contribution savings plans equal three percent eligible employee earnings plus matching two percent eligible employee earnings based employee contributions plan total scheringplough contributions plan million million respectively earnings per common share following table reconciles components basic diluted earningsloss per share computations dollars shares millions eps numerator net incomeloss cumulative effect change accounting principle preferred stock dividends add cumulative effect change accounting principle net tax less preferred stock dividends net incomeloss available common shareholders eps denominator average shares outstanding basic eps dilutive effect options deferred stock units average shares outstanding diluted eps equivalent common shares issuable scheringploughs stock incentive plans excluded computation diluted eps effect would antidilutive million million million respectively years ended december respectively addition years ended december million million million common shares respectively obtainable upon conversion mandatory convertible preferred stock excluded computation diluted earnings per share effect would antidilutive table contents notes consolidated financial statements continued accumulated comprehensive loss components accumulated comprehensive incomeloss december follows dollars millions foreign currency translation adjustment minimum pension liability net tax effects accordance sfas provisions pension postretirement liabilities net tax effects accordance sfas provisions unrealized gain investments available sale net tax total see note retirement plans postretirement benefits additional information regarding impacts scheringploughs financial statements upon adoption sfas effective december scheringplough accounts retirement postretirement benefit plans accordance sfas implementation sfas resulted increase million net tax effects accumulated comprehensive loss reduced shareholders equity gross unrealized pretax gains investments million million respectively unrealized losses immaterial inventories inventories consisted following december dollars millions finished products goods process raw materials supplies total inventories inventory classified noncurrent assets included noncurrent assets million inventory expected sold within one year inventories valued lastin firstout lifo basis comprised approximately percent percent total inventories december respectively estimated replacement cost total inventories december million million respectively cost inventories determined firstin firstout method fifo table contents notes consolidated financial statements continued intangible assets components intangible assets net follows december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net dollars millions patents licenses trademarks total intangible assets included pension assets million december effective december pension assets eliminated result scheringploughs adoption sfas see note retirement plans postretirement benefit plans additional information patents licenses trademarks amortized straightline method respective useful lives residual value intangible assets estimated zero fourth quarter scheringplough received rights trademarks tradenames entity minority interest trademarks tradenames fair value approximately million trademarks tradenames included scheringploughs intangible assets december amortized straightline method years included intangible assets approximately million related license copromotion agreements bayer amounts amortized effective useful lives agreements ranging seven years see note product licenses acquisitions additional information transactions amortization expense related intangible assets million million million respectively included primarily selling general administrative expenses statement consolidated operations intangible assets reviewed determine recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review annual amortization expenses related intangible assets years expected approximately million product licenses acquisitions august scheringplough announced exercised right develop commercialize centocor inc centocor golimumab new antitnfalpha monoclonal antibody developed therapy treatment rheumatoid arthritis immunemediated inflammatory diseases pursuant exercise scheringplough received exclusive worldwide marketing rights golimumab excluding us japan china including hong kong taiwan indonesia exchange rights agreement scheringplough made upfront payment amount million centocor tax benefit million payment included research development expenses year ended december scheringplough sharing development costs centocor scheringplough centocor collaborating resolving difference parties opinions expiration date scheringploughs rights golimumab august scheringplough received determination arbitration rights market golimumab extend years first commercial sales territories centocor appealed ruling effective september scheringplough restructured integrilin copromotion agreement millennium terms restructured agreement scheringplough acquired exclusive us development commercialization rights integrilin exchange upfront payment million royalties integrilin sales scheringplough agreed pay minimum royalties million per year millennium table contents notes consolidated financial statements continued scheringplough also purchased existing integrilin inventory millennium million upfront payment capitalized included intangible assets scheringplough entered collaboration license agreement toyama chemical co ltd toyama terms agreement scheringplough acquired exclusive worldwide rights excluding japan korea china develop use sell garenoxacin human veterinary uses excluding topical ophthalmic applications garenoxacin toyamas quinolone antibacterial agent currently regulatory review us connection execution agreement scheringplough incurred charge second quarter front fee million toyama amount expensed reported research development year ended december scheringplough entered strategic agreement bayer intended enhance scheringploughs pharmaceutical resources terms agreement schering plough exclusive rights us puerto rico market sell distribute avelox cipro antibiotics uses excluding certain topical formulations administration eye ear scheringplough pays bayer royalties generally excess percent products based sales agreement scheringplough also undertook bayers us commercialization activities erectile dysfunction medicine levitra bayers copromotion agreement glaxosmithkline plc japanese market bayer comarket scheringploughs cholesterolabsorption inhibitor zetia approved scheringplough received recorded deferred revenue million related sale zetia copromotion rights bayer deferred revenue begin recognized upon regulatory approval japan zetia currently regulatory review japan certain circumstances zetia receive regulatorymarketing approval japan certain date amount required repaid bayer agreement bayer potentially restricts scheringplough marketing products us would compete products agreement result schering plough expects sublicense rights garenoxacin quinolone antibacterial agent scheringplough licensed toyama shortterm borrowings longterm debt commitments short longterm borrowings scheringploughs outstanding borrowings december follows dollars millions shortterm commercial paper shortterm borrowings current portion longterm debts current portion capital leases total shortterm borrowings longterm year senior unsecured notes year senior unsecured notes capital leases total longterm borrowings scheringploughs shortterm borrowings consist primarily bank loans commercial paper issued us weighted average interest rate shortterm borrowings percent percent december respectively table contents notes consolidated financial statements continued senior unsecured notes november scheringplough issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due net proceeds offering billion interest notes payable semiannually subject rate adjustment follows rating assigned particular series notes either moodys investors service inc moodys standard poors rating services sp changes rating set forth interest rate payable series notes initial interest rate percent notes due percent notes due plus additional interest rate set forth moodys sp additional interest rate moodys rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade either moodys sp respectively notes subsequently rated baa moodys bbb sp upon issuance notes rated moodys sp july moodys lowered rating notes baa accordingly interest payable note increased basis points effective december resulted percent interest rate payable notes due percent interest rate payable notes due increased december notes rated baa moodys sp senior unsecured notes redeemable whole part scheringploughs option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes credit facilities scheringplough billion credit facility matures may requires scheringplough maintain total debt capital ratio percent credit line available general corporate purposes considered support scheringploughs commercial paper borrowings borrowings credit facility may drawn us parent company whollyowned international subsidiaries accompanied parent guarantee facility require compensating balances however nominal commitment fee paid december million drawn facility whollyowned international subsidiary purposes funding repatriations ajca borrowing amount fully repaid december borrowings outstanding facility addition credit facility scheringplough entered million credit facility fourth quarter purposes funding repatriations ajca december entire amount drawn whollyowned international subsidiary fund repatriations facility paid full terminated addition scheringploughs international subsidiaries approximately million available unused lines credit various financial institutions december table contents notes consolidated financial statements continued commitments total rent expense amounted million million million respectively future annual minimum rental commitments next five years non cancelable operating leases december follows million million million million million aggregate minimum lease obligations million due thereafter december scheringplough commitments totaling million million related capital expenditures made respectively financial instruments sfas derivative instruments financial hedging activities amended requires derivatives recorded balance sheets fair value addition statement also requires effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized income occur risks policy objectives scheringplough exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes currently schering plough deemed cost effective engage formulabased program hedging profits cash flows international operations using derivative financial instruments limited basis scheringplough hedge selective foreign currency risks derivatives scheringploughs international subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provide natural level protection adverse changes exchange rates furthermore risk adverse exchange rate change somewhat mitigated fact scheringploughs international operations widespread scheringplough mitigates credit risk derivative instruments dealing counterparties considered high credit quality accordingly scheringplough anticipate loss nonperformance scheringplough enter derivative instruments generate trading profits table presents carrying values estimated fair values certain scheringploughs financial instruments december estimated fair values determined based market prices available dealer quotes carrying values financial instruments including cash cash equivalents approximated estimated fair values december carrying estimated carrying estimated value fair value value fair value dollars millions assets shortterm investments longterm investments liabilities shortterm borrowings current portion longterm debt longterm debt table contents notes consolidated financial statements continued longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held nonqualified trusts fund longterm employee benefit obligations included liabilities consolidated balance sheets assets used fund related liabilities shareholders equity scheringplough authorized shares preferred stock consists preferred shares designated series junior participating preferred stock preferred shares designated percent mandatory convertible preferred stock preferred shares whose designations yet determined percent mandatory convertible preferred stock shelf registration august scheringplough issued shares percent mandatory convertible preferred stock preferred stock face value billion net proceeds scheringplough billion deducting commissions discounts underwriting expenses share preferred stock automatically convert common shares scheringplough depending average closing price scheringploughs common shares period immediately preceding mandatory conversion date september defined prospectus preferred shareholders may elect convert time prior september minimum conversion ratio common shares per share preferred stock additionally time prior mandatory conversion date closing price scheringploughs common shares exceeds least trading days within period consecutive trading days scheringplough may elect cause conversion less preferred stock outstanding minimum conversion ratio common shares preferred share preferred stock accrues dividends annual rate percent shares outstanding dividends cumulative date issuance extent scheringplough legally permitted pay dividends board directors declares dividend payable scheringplough pay dividends dividend payment date dividend payment dates march june september december first dividend paid december december scheringplough ability issue million principal amount securities currently effective securities exchange commission sec shelf registration treasury stock summary treasury share transactions years ended december follows shares millions share balance january stock incentive plans activities share balance december table contents notes consolidated financial statements continued included treasury share balance million shares acquired subsidiary scheringplough openmarket purchase program shares considered treasury shares new jersey law however like treasury shares may voted considered outstanding shares determining necessary votes approve matter submitted stockholder vote subsidiary receive dividends shares preferred share purchase rights scheringplough preferred share purchase rights outstanding attached presently trade scheringploughs common shares exercisable rights become exercisable person group acquires percent scheringploughs common stock announces tender offer completed would result ownership person group percent scheringploughs common stock person group acquire percent scheringploughs outstanding common stock merger business combination transaction right entitle holder acquirer purchase common shares scheringplough market value twice exercise price right exercise price rights following acquisition person group beneficial ownership percent less percent scheringploughs common stock board directors may call exchange rights rights owned acquirer whole part exchange ratio one common share one twohundredth share series junior participating preferred stock per right also prior acquisition person group beneficial ownership percent scheringploughs common stock rights redeemable per right option board directors rights expire july unless earlier redeemed exchanged board directors also authorized reduce percent thresholds referred less greater sum percent largest percentage outstanding shares common stock known scheringplough beneficially owned person group affiliated associated persons ii percent except following acquisition person group beneficial ownership percent scheringploughs common stock reduction may adversely affect interests holders rights insurance coverage scheringplough maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly result recent external events availability insurance become restrictive scheringplough considers impact changes continually assesses best way provide insurance needs future scheringplough selfinsures substantial proportion risk relates products liability table contents notes consolidated financial statements continued segment information scheringplough three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent scheringploughs current management reporting structure prescription pharmaceuticals segment discovers develops manufactures markets human pharmaceutical products consumer health care segment develops manufactures markets overthecounter foot care sun care products primarily us animal health segment discovers develops manufactures markets animal health products net sales major product segment dollars millions prescription pharmaceuticals remicade nasonex pegintron clarinexaerius temodar claritin rx integrilin rebetol avelox introna caelyx subutex elocon cipro pharmaceutical consumer health care otc foot care sun care animal health consolidated net sales net sales geographic area dollars millions united states europe canada pacific area asia latin america total international consolidated net sales table contents notes consolidated financial statements continued scheringplough subsidiaries countries outside us net sales presented geographic area scheringploughs customers located following foreign countries accounted percent consolidated net sales past three years consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions total international net sales france japan canada italy net sales customer sales single customer accounted percent scheringploughs consolidated net sales past three years follows consolidated consolidated consolidated net sales net sales net sales net sales net sales net sales dollars millions mckesson corporation cardinal health profit segment e r ended decem r dollars millions prescription pharmaceuticals consumer health care animal health corporate including net interest income million million respectively million net interest expense consolidated profitloss tax cumulative effect change accounting principle scheringploughs net sales include sales vytorin zetia managed partnership merck scheringplough accounts joint venture equity method accounting see note equity income cholesterol joint venture additional information profit prescription pharmaceuticals segment includes equity income cholesterol joint venture corporate includes interest income expense foreign exchange gains losses headquarters expenses special charges miscellaneous items accounting policies used segment reporting described note summary significant accounting policies corporate includes special charges million primarily related changes scheringploughs manufacturing operations us puerto rico announced june related prescription pharmaceuticals segment included cost sales charges approximately table contents notes consolidated financial statements continued million manufacturing streamlining actions primarily related prescription pharmaceuticals segment corporate includes special charges million including million employee termination costs million asset impairment charges increase litigation reserves million resulting total reserve million representing scheringploughs current estimate resolve massachusetts investigation well investigations state litigation disclosed awp litigation investigations note legal environmental regulatory matters estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate includes special charges million including million employee termination costs well million asset impairment charges million closure costs primarily related exit small european research development facility estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million supplemental sales information sales products comprising percent scheringploughs us international sales year ended december follows mount p ercentage dollars millions us nasonex international remicade pegintron longlived assets geographic location dollars millions united states singapore ireland puerto rico total longlived assets shown geographic location primarily property scheringplough disaggregate assets segment basis internal management reporting therefore information presented consent decree may scheringplough agreed fda entry consent decree resolve issues related compliance current good manufacturing practices cgmp certain scheringploughs facilities new jersey puerto rico consent decree decree table contents notes consolidated financial statements continued summary decree required scheringplough make payments totaling million two equal installments million paid addition decree required scheringplough complete revalidation programs manufacturing processes used produce bulk active pharmaceutical ingredients finished drug products covered facilities well implement comprehensive cgmp work plan facility decree required foregoing completed accordance strict schedules provided possible imposition additional payments event scheringplough adhere approved schedules final completion work made subject certification independent experts whose certifications turn made subject fda acceptance september scheringplough completed revalidation third party certification bulk active pharmaceutical ingredients december schering plough completed revalidation thirdparty certification finished drug products scheringplough also completed significant steps cgmp work plan december requirements completed accordance schedules required decree scheringplough obtained thirdparty certification completion work plan required decree possible fda may disagree experts certification event possible fda may assess additional payments permitted decree described detail general cgmp work plan contained significant steps whose timely satisfactory completion subject payments thousand per business day deadline missed payments may exceed million million years payments subject overall cap million scheringplough would expense additional payments assessed decree incurred terms decree provided fda notified scheringplough significant violation fda law regulations decree fiveyear period since decrees entry may scheringplough may petition court decree dissolved fda oppose scheringploughs petition assurance particular date consent decree lifted legal environmental regulatory matters background scheringplough involved various claims investigations legal proceedings scheringplough records liability contingencies probable liability incurred amount reasonably estimated scheringplough adjusts liabilities contingencies reflect current best estimate probable loss minimum liability case may best estimate determinable scheringplough records minimum amount within probable range liability expected insurance recoveries considered determining amounts recorded liabilities environmental related matters scheringplough believes loss contingency reasonably possible rather probable amount loss estimated liability recorded however liability reasonably possible disclosure loss contingency made scheringplough reviews status claims investigations legal proceedings ongoing basis including related insurance coverages time time scheringplough may settle otherwise resolve matters terms conditions management believes best interests scheringplough resolution claims investigations legal proceedings individually aggregate could material adverse effect scheringploughs results operations cash flows financial condition addition resolution investigations could involve injunctive administrative remedies would adversely impact business exclusion government reimbursement programs turn would material adverse impact business future financial condition cash flows results operations table contents notes consolidated financial statements continued except matters discussed remainder note recorded liabilities contingencies december related expenses incurred year ended december material opinion management based advice legal counsel ultimate outcome matters except matters discussed remainder note material impact scheringploughs results operations cash flows financial condition patent matters described patents trademarks intellectual property rights part business intellectual property protection critical scheringploughs ability successfully commercialize product innovations potential litigation regarding scheringploughs intellectual property rights always exists may initiated third parties attempting abridge scheringploughs rights well scheringplough protecting rights patent matters described potential material effect scheringplough dr scholls freeze away patent july orasure technologies filed action us district court eastern district pennsylvania alleging patent infringement scheringplough healthcare products sale dr scholls freeze away wart removal product complaint seeks permanent injunction unspecified damages including treble damages massachusetts investigation august scheringplough announced reached agreement us attorneys office district massachusetts settle investigation involving schering ploughs sales marketing clinical trial practices programs along warrick pharmaceuticals warrick scheringploughs generic subsidiary massachusetts investigation investigation focused following alleged practices providing remuneration managed care organizations physicians others induce purchase schering pharmaceutical products offlabel marketing drugs submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program agreement provided aggregate settlement amount million criminal fine million million resolve civil aspects investigation january schering sales corporation subsidiary scheringplough pled guilty one count conspiracy make false statements government connection settlement scheringplough signed addendum existing corporate integrity agreement office inspector general us department health human services addendum affect schering ploughs ongoing business customers including federal government table contents notes consolidated financial statements continued scheringplough recorded liability million related massachusetts investigation well investigations state litigation described awp litigation investigations settlement amount million relates massachusetts investigation awp litigation investigations ongoing awp litigation investigations scheringplough continues respond existing new litigation certain states private payors investigations department health human services department justice several states industry scheringplough practices regarding average wholesale price awp scheringplough cooperating investigations litigations investigations relate whether awp used pharmaceutical companies certain drugs improperly exceeds average prices paid providers consequence results unlawful inflation certain reimbursements drugs state programs private payors based awp complaints allege violations federal state law including fraud medicaid fraud consumer protection violations among claims majority cases plaintiffs seeking class certifications cases classes certified outcome litigations investigations could include substantial damages imposition substantial fines penalties injunctive administrative remedies securities class action litigation federal securities litigation following scheringploughs announcement fda conducting inspections scheringploughs manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices several lawsuits filed scheringplough certain named officers lawsuits allege defendants violated federal securities law allegedly failing disclose material information making material misstatements specifically allege scheringplough failed disclose alleged serious risk new drug application clarinex would delayed result manufacturing issues allege scheringplough failed disclose alleged depth severity manufacturing issues complaints consolidated one action us district court district new jersey consolidated amended complaint filed october purporting represent class shareholders purchased shares scheringplough stock may february complaint seeks compensatory damages behalf class court certified shareholder class october discovery ongoing shareholder derivative actions two lawsuits filed us district court district new jersey scheringplough certain officers directors former director seeking damages behalf scheringplough including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints allege failure disclose material information breach fiduciary duty directors relating fda inspections investigations scheringploughs pricing practices sales marketing clinical trials practices lawsuits shareholder derivative actions purport assert claims behalf scheringplough two shareholder derivative actions pending us district court district new jersey consolidated one action august erisa litigation march scheringplough served putative class action complaint filed us district court new jersey alleging scheringplough retired chairman ceo president richard jay kogan scheringploughs employee savings plan plan administrator several current former directors certain corporate officers messrs larosa moore breached fiduciary obligations certain participants table contents notes consolidated financial statements continued plan complaint seeks damages amount losses allegedly suffered plan complaint dismissed june plaintiffs appealed august us court appeals third circuit reversed dismissal district court matter remanded back district court proceedings kdur antitrust litigation scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upsher smith filed abbreviated new drug applications following commencement ftc administrative proceeding alleging anticompetitive effects settlements alleged class action suits filed federal state courts behalf direct indirect purchasers k dur scheringplough upshersmith lederle suits claim violations federal state antitrust laws well state statutory common law causes action suits seek unspecified damages discovery ongoing thirdparty payor actions several supported class action litigations filed following announcement settlement massachusetts investigation plaintiffs actions seek damages behalf thirdparty payors resulting allegations offlabel promotion improper payments physicians issue massachusetts investigation tax matters october irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september scheringplough made payments irs amount million income tax million interest scheringplough filed refund claims tax interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount tax interest refund litigation currently discovery phase scheringploughs tax reserves adequate cover mentioned payments pending administrative obligations connection settlement investigation us department justice us attorneys office eastern district pennsylvania scheringplough entered fiveyear corporate integrity agreement cia cia amended august connection settlement massachusetts investigation commencing new fiveyear term disclosed note consent decree scheringplough subject obligations consent decree fda failure comply obligations cia consent decree result financial penalties matters nitrodur investigation august scheringplough received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning scheringploughs classification nitrodur medicare rebate purposes scheringploughs use nominal pricing bundling product sales scheringplough cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates table contents notes consolidated financial statements continued french matter based complaint french competition authority competitor france pursuant court order french competition authority obtained documents french subsidiary scheringplough relating one products subsidiary markets sells resolution matter adverse french subsidiary could result imposition civil fines injunctive administrative remedies environmental scheringplough responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law scheringplough alleged potentially responsible party prp schering plough believes remote time material liability relation sites scheringplough estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps scheringplough records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries company december related consolidated statements operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements financial statement schedule responsibility companys management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein discussed note consolidated financial statements effective january company adopted statement financial accounting standards sfas revised sharebased payment also discussed note consolidated financial statements effective december company adopted sfas employers accounting defined benefit pension postretirement plans also audited accordance standards public company accounting oversight board united states effectiveness companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion managements assessment effectiveness companys internal control financial reporting unqualified opinion effectiveness companys internal control financial reporting deloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries quarterly data unaudited three nths ended march june september december dollars millions except per share figures net sales cost sales gross margin selling general administrative research development incomeexpense net special charges equity income cholesterol joint venture income income taxes income tax expense net incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net tax net incomeloss dividends preferred shares net incomeloss available common shareholders diluted earningsloss per common share earningloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax diluted earnings per common share basic earningsloss per common share earningsloss available common shareholders cumulative effect change accounting principle cumulative effect change accounting principle net tax basic earningsloss per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions table contents net sales third quarter included favorable impact approximately million resulting reversal previously accrued rebate amounts tricare retail pharmacy program us federal court appeals ruled pharmaceutical manufacturers obligated pay see note special charges manufacturing changes consolidated financial statements additional information relating special charges charges schering ploughs announced manufacturing changes scheringploughs approximate number holders record common shares january item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated scheringploughs disclosure controls procedures end period covered k concluded scheringploughs disclosure controls procedures effective also concluded changes scheringploughs internal control financial reporting occurred scheringploughs recent fiscal quarter materially affected reasonably likely materially affect scheringploughs internal control financial reporting part changing business environment scheringplough operates scheringplough replacing upgrading number information systems process ongoing several years connection changes part scheringploughs management internal control financial reporting disclosure controls procedures management concluded new systems least effective respect controls prior systems managements report internal control financial reporting management scheringplough corporation responsible establishing maintaining adequate internal control financial reporting scheringploughs internal control system designed provide reasonable assurance scheringploughs management board directors regarding preparation fair presentation published financial statements internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation presentation scheringploughs management assessed effectiveness scheringploughs internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal control integrated framework based assessment management believes december scheringploughs internal control financial reporting effective scheringploughs independent registered public accounting firm deloitte touche llp issued attestation report managements assessment scheringploughs internal control financial reporting firms report follows table contents report independent registered public accounting firm board directors shareholders scheringplough corporation audited managements assessment included accompanying managements report internal control financial reporting scheringplough corporation subsidiaries company maintained effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion managements assessment opinion effectiveness companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting evaluating managements assessment testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe audit provides reasonable basis opinions companys internal control financial reporting process designed supervision companys principal executive principal financial officers persons performing similar functions effected companys board directors management personnel provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting including possibility collusion improper management override controls material misstatements due error fraud may prevented detected timely basis also projections evaluation effectiveness internal control financial reporting future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion managements assessment company maintained effective internal control financial reporting december fairly stated material respects based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission also audited accordance standards public company accounting oversight board united states consolidated financial statements financial statement schedule year ended december company report dated february report included explanatory paragraph regarding companys adoption statement financial accounting standards sfas revised sharebased payment sfas employers accounting defined benefit pension postretirement plans expressed unqualified opinion financial statements financial statement schedule deloitte touche llp parsippany new jersey february table contents part iii item directors executive officers registrant information concerning directors nominees directors incorporated reference proposal one elect eleven directors oneyear term scheringploughs proxy statement annual meeting shareholders may information concerning executive officers included part filing caption executive officers registrant information concerning compliance section exchange act incorporated reference section beneficial ownership reporting compliance scheringploughs proxy statement annual meeting shareholders may information concerning audit committee audit committee financial expert incorporated reference information audit committee board directors practices committees board directors scheringploughs proxy statement annual meeting shareholders may scheringplough adopted code business conduct ethics standards global business practices applicable employees including chief executive officer chief financial officer controller scheringploughs standards global business practices available investor relations section scheringploughs website wwwscheringploughcom addition written copy materials provided charge writing office corporate secretary scheringplough corporation galloping hill road mail stop k kenilworth new jersey scheringplough intends satisfy disclosure requirement item form k regarding amendment waiver provision standards global business practices posting information website address specified item executive compensation information concerning executive compensation incorporated reference executive compensation scheringploughs proxy statement annual meeting shareholders may information concerning director compensation incorporated reference director compensation scheringploughs proxy statement annual meeting shareholders may item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management incorporated reference stock ownership scheringploughs proxy statement annual meeting shareholders may table contents equity compensation plan information following information relates plans equity securities scheringplough may issued employees directors schering plough plans equity securities may issued nonemployees except stock incentive plans certain stock options may transferable family members employeeoptionee related trusts column column b column c number securities remaining available number securities future issuance issued weightedaverage equity upon exercise exercise price compensation outstanding outstanding plans excluding options warrants options securities reflected plan category rights warrants rights column equity compensation plans approved security holders stock incentive plan stock incentive plan stock incentive plan stock incentive plan directors stock award plan na na equity compensation plans approved security holders scheringplough ireland approved profit sharing scheme na na total plan permits eligible employees work scheringplough irish subsidiary enjoy tax advantages christmas bonus percent percent pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts euro may deferred year employee employees may sell withdraw shares allocated accounts two three years item certain relationships related transactions information concerning certain relationships related transactions incorporated reference certain transactions procedures related party transactions director independence assessments scheringploughs proxy statement annual meeting shareholders may information concerning director independence incorporated reference director independence scheringploughs proxy statement annual meeting shareholders may item principal accountant fees services information concerning principal accountant fees services incorporated reference proposal two ratify designation deloitte touche llp audit scheringploughs books accounts scheringploughs proxy statement annual meeting shareholders may part iv item exhibits financial statement schedules following documents filed part report financial statements financial statements set forth item k financial statement schedules merckscheringplough cholesterol partnership combined financial statements index p age combined statements net sales contractual expenses years ended december combined balance sheets december combined statements cash flows years ended december combined statements partners capital years ended december notes combined financial statements years ended december independent auditors report schedule ii valuation qualifying accounts schedules listed omitted applicable required table contents index exhibits unless otherwise indicated exhibits part commission file number exhibit number description location amended restated certificate incorporation incorporated reference exhibit scheringploughs q period ended june b amended restated bylaws incorporated reference exhibit b scheringploughs q period ended june rights agreement scheringplough bank new york dated incorporated reference exhibit scheringploughs filed june june b form participation rights agreement scheringplough chase incorporated reference exhibit scheringploughs registration manhattan bank national association trustee statement form amendment filed december file ci indenture dated november scheringplough bank incorporated reference exhibit scheringploughs k filed new york trustee november cii first supplemental indenture including form note dated november incorporated reference exhibit scheringploughs k filed november ciii second supplemental indenture including form note dated november incorporated reference exhibit scheringploughs k filed november civ global senior note due incorporated reference exhibit civ scheringploughs k year ended december cv global senior note due incorporated reference exhibit cv scheringploughs k year ended december directors compensation plan amended restated effective june incorporated reference exhibit hiii scheringploughs q amendments september period ended september bi stock incentive plan incorporated reference exhibit scheringploughs q period ended september bii amendment stock incentive plan effective february incorporated reference exhibit scheringploughs q period ended march biii amendment stock incentive plan effective february incorporated reference exhibit c scheringploughs k year ended december c stock incentive plan amended february incorporated reference exhibit scheringploughs k year ended december stock incentive plan amended restated effective may incorporated reference exhibit diii scheringploughs q amendments september period ended september table contents exhibit number description location ei letter agreement dated november robert bertolini schering incorporated reference exhibit eiii scheringploughs k plough year ended december eii employment agreement effective upon change control dated incorporated reference exhibit scheringploughs k filed december robert bertolini scheringplough corporation december eiii employment agreement dated may carrie cox incorporated reference exhibit scheringploughs k filed may scheringplough eiv employment agreement dated april fred hassan incorporated reference exhibit scheringploughs k filed april scheringplough ev employment agreement dated december thomas p attached koestler phd scheringplough evi employment agreement dated december raul kohan attached scheringplough evii letter agreement dated march thomas j sabatino jr incorporated reference exhibit scheringploughs q period scheringplough ended march eviii employment agreement effective upon change control dated april attached thomas j sabatino jr scheringplough eix form employment agreement effective upon change control attached scheringplough certain executives new agreements beginning december f operations management team incentive plan amended restated effective incorporated reference exhibit mii scheringploughs q june period ended september g cash longterm incentive plan amended restated effective january incorporated reference exhibit n scheringploughs k year ended december h longterm performance share unit incentive plan amended restated incorporated reference exhibit scheringploughs k year effective january ended december transformational performance contingent shares program incorporated reference exhibit p scheringploughs k year ended december j severance benefit plan amended restated effective december incorporated reference exhibit exi scheringploughs q amendments april period ended march k savings advantage plan amended restated effective june incorporated reference exhibit exiii scheringploughs q period ended september l supplemental executive retirement plan amended restated january attached table contents exhibit number description location retirement benefits equalization plan amended restated january incorporated reference exhibit l scheringploughs k year ended december n executive incentive plan amended restated october incorporated reference exhibit ai scheringploughs k year ended december deferred compensation plan amended restated october incorporated reference exhibit scheringploughs k year ended december p amended restated defined contribution trust incorporated reference exhibit aii scheringploughs k year ended december q amended restated serp rabbi trust agreement incorporated reference exhibit g scheringploughs k year ended december r cholesterol governance agreement dated may among incorporated reference exhibit scheringploughs k dated scheringplough merck co inc parties signatory thereto october first amendment cholesterol governance agreement dated incorporated reference exhibit scheringploughs k filed december among scheringplough merck co inc october parties signatory thereto master agreement dated december among schering incorporated reference exhibit scheringploughs k filed plough merck co inc parties signatory thereto october u letter agreement dated april relating consent decree incorporated reference exhibit scheringploughs q period ended march v distribution agreement scheringplough centocor inc dated april incorporated reference exhibit u scheringploughs amended k year ended december filed may computation ratio earnings fixed charges attached standards global business practices covers employees including senior incorporated reference exhibit scheringploughs k filed financial officers september subsidiaries registrant attached consent independent registered public accounting firm attached independent auditors consent attached power attorney attached sarbanesoxley act section certification chairman board attached chief executive officer sarbanesoxley act section certification executive vice president attached chief financial officer table contents exhibit number description location sarbanesoxley act section certification chairman board attached chief executive officer sarbanesoxley act section certification executive vice president attached chief financial officer compensatory plan contract arrangement certain portions exhibit omitted pursuant request confidential treatment nonpublic information filed separately securities exchange commission pursuant rule b securities exchange act amended copies